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Esther Marie Levasseur 
ROLE OF DHS IN TRANSLATION CONTROL OF ISLET β-CELL REPLICATION 
DURING HIGH FAT INDUCED OBESITY AND GLUCOSE INTOLERANCE  
 
Insulin resistance in liver, muscle, and adipose tissue almost invariably occurs 
during obesity. To compensate, the insulin-producing β-cell increases insulin production 
by expanding cellular mass. The inability of the β-cell to fully compensate leads to 
hyperglycemia and ultimately type 2 diabetes. The enzyme deoxyhypusine synthase 
(DHS) catalyzes the spermidine-dependent posttranslational modification of Lys50 of 
eukaryotic translation initiation factor 5A (eIF5A) to form hypusine (Hyp). Studies have 
demonstrated this modification of eIF5A to contribute to cellular proliferation in 
cancerous cells, but its role in the physiologic proliferation of islet β-cells is unknown. I 
hypothesized eIF5A-Hyp to be required for the proliferation of islet β cells during the 
early phase of insulin resistance, allowing the β-cell to respond to the increased demand 
for insulin to maintain glucose homeostasis. To test this hypothesis, deletion of DHS was 
induced post-developmentally in β-cells by crossing Dhs-fl/fl mice with MIP1-CreERT 
mice, and animals were fed for 1 or 4 weeks with a 60% kcal from fat diet (HFD) or 
normal chow diet (NCD, 16% kcal from fat diet). NCD-fed and HFD-fed animals had 
normal glucose homeostasis after one week feeding, regardless of genotype.  However, 
after 4 weeks of HFD, KO mice had significantly worse glucose intolerance compared to 
control mice. eIF5A-Hyp levels increased in β-cells of control animals and as expected 
remained low in the KO mice. β-cell proliferation was significantly increased after 1 week 
of HFD as measured by PCNA staining, however KO mice showed no increase. Cyclin 
D2 protein, but not mRNA, was increased in control animals fed a HFD; this protein 
increase was not observed in KO animals.  Furthermore, polyribosomal profile of 
isolated islets of 1 week HFD-fed mice showed the Ccnd2 mRNA bound to the 
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monoribosome fractions in the KO animals compared to the controls, resulting in 
changes of global translation. Interestingly, Ccnd1 polyribosome to monoribosome ratio 
showed no changes in translation compared to Ccnd2. Taken together, these results 
suggest that DHS (and, consequently, eIF5A-Hyp) is necessary for the adaptive 
proliferative and functional response of β-cells during high fat diet induced obesity and 
glucose intolerance.  
 
 
Raghavendra G Mirmira, MD, PhD, Chair 
 
 vii
TABLE OF CONTENTS 
LIST OF FIGURES ......................................................................................................... ix 
ABBREVIATIONS .......................................................................................................... xi 
CHAPTER I - INTRODUCTION  ..................................................................................... 1 
I.A.  Pancreas Structure and Function 
I.B. The Islet β-Cell and Glucose Homeostasis  
I.C. Transcriptional Regulation in β-cell Development and Function  
I.D. β-cell Dysfunction in the Development of Diabetes 
I.E. Cell Cycle 
I.F. Regulation of mRNA Translation in the β-cell 
I.G. Conclusion and Hypothesis 
CHAPTER II - RESEARCH DESIGN AND METHODS ..................................................30 
CHAPTER III - TRANSIENT β-CELL DEATH DURING OBESITY AND GLUCOSE 
INTOLERANCE .............................................................................................................40 
III.A. Introduction  
III.B. Results  
III.C. Discussion  
CHAPTER IV - DHS AS A MODULATOR OF β-CELL REPLICATION DURING 
COMPENSATION .........................................................................................................53 
IV.A. Introduction  
IV.B. Results  
IV.C. Discussion  
CHAPTER V - CONCLUSIONS AND FUTURE DIRECTIONS ......................................79 
V.A. The adaptive response to overnutrition: β-cell replication  
 viii 
V.B. The maladaptive response to overnutrition: β-cell death 
V.C. Stress-induced plasticity of β-cells: a fate better than death? 
REFERENCES ..............................................................................................................89 
CURRICULUM VITAE 
  
 ix
LIST OF FIGURES 
1. Insulin Resistance..................................................................................................... 8 
2. Cell Cycle ................................................................................................................14 
3. Activation of Proliferation  ........................................................................................17 
4. Mechanism of Eukaryotic Translation ......................................................................23 
5. Hypusination of eIF5A .............................................................................................27 
6. Mouse DMD assay specificity and validation ...........................................................44 
7. Glucose Intolerance during LFD and HFD feeding in C57BL/6J...............................45 
8. Circulating unmethylated and methylated Ins2 DNA during LFD and HFD 
 feeding in C57BL/6J mice .......................................................................................47 
9. Circulating unmethylated and methylated Ins2 DNA in C57BL/KsJ-db/db  
mice and controls.....................................................................................................49 
10. Insulin staining of pancreas .....................................................................................50 
11. DHS Knockout mouse model is normoglycemic under basal conditions ..................58 
12. Loss of DHS in the islet beta cell results in impaired glucose tolerance and  
beta cell mass decline .............................................................................................61 
13. Circulating unmethylated and methylated Ins2 DNA during HFD feeding in  
DHS∆β mice ............................................................................................................62 
14. Cell growth impaired in DHS∆β mice .......................................................................63 
15. Cell morphology changes after 4 weeks of HFD in DHS∆β mice ..............................64 
16. Improved insulin secretion in DHS deficient β-cells mice after 1 week of 
 HFD ........................................................................................................................66 
17. DHS deficiency results in an impaired β-cell proliferative response following  
1-week HFD .............................................................................................................67 
18. Cyclin-D2 protein synthesis downregulated in DHS∆β mice .....................................68 
 x
19. Cyclin-D2 protein synthesis halted by translation initiation block in DHS∆β  
mice .........................................................................................................................70 
20. P-PKCζ knockdown affects upstream of DHS activity ..............................................72 
21. mTOR pathway unaffected by chemical inhibition of DHS activity ............................74 
22. Novel pathway of early compensatory proliferation in the pancreatic β-cell ..............78 
 
  
 xi
ABBREVIATIONS 
AKT .................................................................................... AKT Serine/Threonine kinase 
ARX ...................................................................................... Aristaless-related homeobox 
ATP ............................................................................................ Adenosine trisphosphate 
ATRX................................................................................................... X-linked helicase II 
BIP .............................................................. Immunoglobulin heavy-chain binding protein 
CDC45 ............................................................................................. Cell division cycle 45 
CDK ........................................................................................... Cyclin dependent kinase 
CDKN1A .................................................................. Cyclin dependent kinase inhibitor 1A 
CHEK2 .............................................................................................. Checkpoint kinase 2 
CHOP ..................................................................................... C/EBP homologous protein 
DHS .......................................................................................... Deoxyhypusine synthase   
DOHH....................................................................................Deoxyhypusine hydroxylase 
eIF2α ................................................................. eukaryotic translation initiation factor 2 α   
eIF5A ................................................................ eukaryotic translation initiation factor 5 A 
ER ................................................................................................. Endoplasmic reticulum 
FFA ............................................................................................................ Free fatty acid 
GC7 .................................................................................. N1-guanyl-1,7-diaminoheptane 
GH .......................................................................................................... Growth hormone 
GLP-1 ........................................................................................... Glucagon like peptide 1 
GLUT2 .............................................................................................Glucose transporter 2 
GLUT4 .............................................................................................Glucose transporter 4 
GPR40/FFAR1 .......................................................................... Free fatty acid receptor 1 
GTT ............................................................................................... Glucose tolerance test 
GSIS ........................................................................ Glucose stimulated insulin secretion 
 xii
GSK3β ...........................................................................Glycogen synthase kinase 3 beta 
HFD ................................................................................................................ High fat diet 
IAPP ........................................................................................... Islet amyloid polypeptide 
IGF-1 ........................................................................................ Insulin like growth factor 1 
INS2 ........................................................................................................... Insulin gene 2 
IRS-2 ...................................................................................... Insulin receptor substrate 2 
ISL-1 ........................................................................ Insulin gene enhancer protein (Islet) 
JNK ............................................................................................. c-Jun N-terminal kinase 
MAFA ............................................................................MAF BZIP Transcription Factor A 
MAFB ............................................................................MAF BZIP Transcription Factor B 
MAPK ............................................................................. Mitogen activated protein kinase 
MCM2............................................ Minichromosome maintenance complex component 2 
MEN1 ...................................................................................................................... Menin 
MODY ....................................................................... Maturity onset diabetes of the youth 
NEUROD1 ...................................................................................... Neuronal differential 1 
NF2 ......................................................................................................... Neurofibromin 2 
NFAT ............................................................................ Nuclear factor of activated T-cells 
NFκB ................................ Nuclear factor kappa-light-chain-enhancer of activated B cells 
NKX2.2 .................................................................................................. NK2 Homeobox 2 
NKX6.1 .................................................................................................. NK6 Homeobox 1 
NOD ................................................................................................... Non obese diabetic 
PAX4 ............................................................................................................. Paired box 4 
PBS ......................................................................................... Phosphate buffered saline 
PDK1 ........................................................................... Pyruvate dehydrogenase kinase 1  
PDX1 ..................................................................... Pancreatic and duodenal homeobox 1 
 xiii 
PERK ................................................................ PRKR-like endoplasmic reticulum kinase 
PI3K ........................................................................................ Phosphoinositide 3-kinase 
PKB ......................................................................................................... Protein kinase B 
PKC ......................................................................................................... Protein kinase C 
PRB .............................................................................................. Retinoblastoma protein 
PRL ..................................................................................................................... Prolactin 
PTEN............................................................................ Phosphatase and tensin homolog 
ROS .......................................................................................... Reactive oxygen species 
RT ....................................................................................................... Room temperature 
SERCA ........................................................... Sarco/endoplasmic reticulum Ca2+-ATPase 
STAT .................................................... Signal transducers and activators of transcription 
TGFB1 ..........................................................................Transforming growth factor beta 1 
T1D ......................................................................................................... Type 1 diabetes 
T2D ......................................................................................................... Type 2 diabetes 
VDCC ............................................................................... Calcium voltage-gated channel 
 
 
 1 
Chapter I 
Introduction 
 
I.A. Pancreas Structure and Function 
The pancreas is a glandular organ comprised of different cellular subtypes whose 
divergent functions include the production of digestive enzymes to maintain whole-body 
glucose homeostasis. The cells of the pancreas are grossly contained within exocrine 
and endocrine tissues. The exocrine tissue accounts for roughly 90% of the total 
pancreatic mass and is responsible for producing and secreting digestive enzymes 
including trypsin, amylase, and lipase into the small intestine. The endocrine tissue of 
the pancreas, accounting for 1-2% of pancreatic mass, is entirely contained within 
discrete clusters known as the islets of Langerhans (or islets). There are approximately 3 
million islets distributed throughout the healthy human pancreas and they are 
surrounded by the exocrine tissue. The islets are comprised of five different type of cells 
and each is responsible for producing specific hormones. The most abundant cell found 
in the islet is the β-cell, which produces insulin and amylin, and comprises about 70% of 
the islet in rodents (and perhaps 40-50% in humans) (1). The α-cell produces glucagon 
and comprises about 20-40% of the total islet. The δ-cell produces somatostatin and can 
be found in about 10% of the islet. The PP-cell, sometimes named γ-cell, produces 
pancreatic polypeptide and comprises about 5% of the pancreas. Lastly, the ε-cell can 
be found in 0-1% in the islet and produces ghrelin. The mouse islet consists of a core of 
β-cells, surrounded by a mantle containing the α-, δ-, PP/ γ-, and the ε-cells, whereas 
the human islet consists of β-cells interspersed with the other cell types. It has been 
proposed that human β-cells are sandwiched in between layers of α-cells folded and 
organized in an U or O shape (2). This proposed organization promotes heterologous 
contacts between α- and β-cells promoting α-cells stimulation on β-cell function, whereas 
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this pattern is missing in mice (3). It has been speculated that this major difference is 
one that partially explains the glucose sensitivity of the human β-cells compared to the 
rodent islets (4). The significance of this difference in cytoarchitecture in rodents vs. 
humans may account for the functional differences that have more recently been 
appreciated between the two species (5). 
 
I.B. The Islet β Cell and Glucose Homeostasis 
The islet β-cell is unique in its ability to synthesize and secrete insulin. Insulin is a 
highly-conserved 51-amino acid peptide hormone that is required for the cellular uptake 
of glucose into adipose and muscle tissue, and for the suppression of glucose output by 
the liver. Insulin and glucagon have opposing anabolic and catabolic functions that work 
in concert to maintain glucose homeostasis. After ingestion of a meal, an increase in 
blood glucose activates the β-cell to secrete and produce insulin through a pathway 
called glucose-stimulated insulin secretion (GSIS). Upon elevation of plasma glucose 
concentration, glucose enters the β-cell by facilitated diffusion through the glucose 
transporter type 2 (GLUT2) on the plasma membrane (6). Following its entry, glucose is 
phosphorylated by glucokinase to form glucose-6-phosphate. Glucokinase is the rate-
limiting enzyme in glucose metabolism and, as such, functions as a glucose “sensor” 
and insulin secretion regulator (7). Glucose-6-phosphate is then subjected to glycolysis, 
which results in the generation of pyruvate in the cytoplasm. Pyruvate then is 
metabolized by pyruvate dehydrogenase to render acetyl CoA and pyruvate carboxylase 
to render oxaloacetate, both increasingly important in the maintenance of the citric acid 
cycle, and therefore facilitating the passage of molecules into the mitochondria. This 
reaction then leads to generation of adenosine triphosphate (ATP) in the respiratory 
chain and is accompanied by efflux of tricarboxylic acid cycle intermediates as 
anaplerosis. ATP production signals the ATP-sensitive K+ channels in the β-cell to close, 
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resulting in membrane depolarization. This membrane depolarization opens L-type 
voltage-dependent Ca2+ channels (VDCC), followed by influx of Ca2+ and elevation of 
cytosolic free Ca2+ concentration. This elevation results in the rapid increase rate of 
insulin exocytosis (8).  
Insulin has a short biologic half-life, thereby allowing for rapid alterations in glucose 
levels in response to physiologic demands. An insulin molecule made endogenously is 
degraded within an hour from its release into the bloodstream (9). To maintain glucose 
homeostasis, insulin binds to its plasma membrane receptor, inducing a conformational 
change and activating the receptor’s tyrosine kinase function. This activation leads to 
autophosphorylation of the β subunit of the insulin receptor and subsequent 
phosphorylation of numerous downstream proteins, insulin receptor substrates, which 
result in transcriptional and post-transcriptional molecular effects (10). This cascade 
leads to the final anabolic process of glucose uptake and its conversion into glycogen, 
fat, and protein. Specifically, in the liver, insulin decreases gluconeogenesis and 
glycogenolysis, while in the striated muscle and adipose tissue, stimulating the storage 
of glucose as glycogen. Any remaining insulin is removed by endocytic processes in 
insulin-sensitive tissues or by reabsorption by the proximal tubular cells of the kidneys. 
Insulin also has an autocrine role in which it impedes the further release of insulin in the 
β-cell (11). Insulin suppresses glucagon production by the α-cell. In the fasted state, 
when glucose and therefore insulin levels are low, glucagon stimulates hepatic 
gluconeogenesis as well as the breakdown of glycogen stored in the liver to increase 
blood glucose levels (12). Together, these two hormones allow the body to constantly 
maintain glucose homeostasis. Under healthy conditions, fasted glucose concentrations 
do not go below 70 mg/dL or increase above 100 mg/dL. Furthermore, 2-hour post-
prandial glucose should not rise above 140mg/dL. Failure of the β-cell to produce 
 4 
significant insulin to meet demand and maintain glucose homeostasis is a common 
feature of both type 1 diabetes (T1D) and type 2 diabetes (T2D). 
 
I.C. Transcriptional Regulation in β-cell Development and Function 
Both the developing and the mature β-cell require numerous transcription factors 
and prohormone convertases to ensure transcription and production of insulin. 
Transcription factors play an important role in the maintenance of β-cell function in 
normal and disease states (13). Their role is to bind to a promoter of a target gene and 
regulate transcription. Transcription is the execution of communication between 
transcription factors and the basal transcriptional machinery (RNA pol II), culminating in 
the progression of RNA pol II through the coding region of the gene resulting in an 
hnRNA transcript. β-cell specific genes are transcribed via both a β-cell specific and 
ubiquitous transcription factors (14). Some of the ubiquitous transcription factors 
involved in insulin regulation include Sp, Creb, and Crem, (15–17), to mention a few. 
The insulin promoter has several cis-regulatory elements, such as A, C and E-box 
elements. These box elements are of importance to facilitate transcription initiation and 
enhance transcriptional activation of the target gene. Pancreatic and duodenal 
homeobox 1 (Pdx1) is a transcription factor central to both pancreas development and 
the maintenance of glucose homeostasis. Pdx1 is first expressed in the early endoderm 
that is destined to form the pancreas, distal stomach, and duodenum (18). In the adult, 
expression of Pdx1 is predominately restricted to the β-cell, although it is also expressed 
at low levels in the δ-cells of the islet as well as the acinar and duct cells. Pdx1 functions 
by binding DNA sequences containing short 5’-TAAT-3’ DNA motifs in the 5’ enhancer 
regions of target genes, and recruiting complexes that regulate the rate of transcription 
(19,20). Studies have shown that the absence or inactivation of Pdx1 as observed in 
Pdx1-/- mice and in humans with PDX1 mutations cause pancreatic agenesis (21,22). 
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Haploinsufficiency of the gene (Pdx1+/- mice) results in maturity onset diabetes of the 
young 4 (MODY4) with impairment in glucose tolerance as a result of impaired insulin 
release (23). Pdx1 is also necessary in the mature pancreas for proper β-cell function, 
and transcriptional regulation of β-cell genes involved in insulin transcription (as 
preproinsulin) and secretion, including preproinuslin, Glut2, Gck (encoding glucokinase), 
MafA, Nkx6.1, and Pdx1 itself (20,24). In the adult Pdx1+/- mouse, Pdx1 deficiency 
results in altered islet morphology, decreased insulin, islet amyloid polypeptide (IAPP), 
and GLUT2 production, impaired GSIS, and glucose intolerance (23).  Pdx1 deficiency 
also leads to decreased β-cell mass, due in part to increased β-cell apoptosis via 
reduction of apoptosis regulator Bcl-2 (25). Pdx1 deficiency also leads to a loss of new 
β-cell formation/regeneration (26). Studies utilizing chromatin immunoprecipation and 
promoter microarray studies revealed numerous additional genes putatively regulated by 
Pdx1, including cell cycle, cell survival, exocytosis, and energy sensing genes (27). 
Combined, these studies indicate that Pdx1 is essential for β-cell development and 
function and suggest that increasing Pdx1 expression may lead to preservation or 
enhancement of functional β-cell mass. Indeed, overexpression of Pdx1 in mouse 
models of β-cell dysfunction enhances β-cell insulin content and GSIS, promotes β-cell 
mass, and glucose tolerance (28,29).   
In addition to Pdx1, the Maf family of transcription factors has been found to play a 
role in β-cell function. These transcription factors are a distinct basic leucine zipper 
family of transcription factors that many studies have found to be important in the 
maintenance of β-cell functionality. MafB is found in both glucagon-producing and 
insulin-producing cells during development, but is restricted to α-cells soon after birth.  
MafB is capable of activating both the insulin and glucagon genes in vitro. In the 
absence of MafB, there is reduced number of insulin and glucagon cells throughout 
development, therefore affecting the number of mature β-cells (30). These data suggest 
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that MafB is involved in regulating gene integration to the formation of both β- and α-
cells during the development of the pancreas. On the other hand, MafA is expressed in 
the mature β-cell and is an essential activator of the insulin gene. MafA is capable of 
activating the insulin gene in non-insulin producing cells (31). Deletion of MafA in mice 
results in β-cell dysfunction, glucose intolerance and impaired proliferation (32). In 
addition, MafA deletion results in a direct reduction of important genes such as insulin, 
NeurodD1 and Glut2, further worsening the functionality of the β-cell during adult stages 
(33). Direct activation of Pdx1 and MafA genes is facilitated by Islet-1 (Isl1), and mature 
β-cells with Isl1 deletion results in reduced levels of Pdx1 and MafA, insulin content, and 
impaired insulin secretion (34). 
A transcription factor that plays an important role in mature islet contributing in 
insulin secretion and glucose homeostasis is NeuroD1. NeuroD1 facilitates insulin 
secretion by modulating the activity of the K+ channel/ATP complex; however, the exact 
mechanism still needs elucidation (35). NeuroD1 deletion reduces Ins1 mRNA 
expression by half resulting in a disruption of the islet architecture.  
Nkx2.2 and Arx are two essential pancreatic transcription factors during 
development that, in their absence during adulthood, results in detrimental 
consequences. Nkx2.2 is required for the specification of many of the endocrine cell 
lineages, whereas Arx is required to obtain the correct ratio of the different cell lineages 
(36). Nkx2.2 is first expressed in the pancreatic progenitor cells but ultimately is 
restricted to specific endocrine cells including α-, β-, PP-, and ε-cells.  Loss of Nkx2.2 
expression results in absence of insulin-producing β-cells and decreased α- and PP-
cells (37). Arx, however, is not expressed in β-cells, and when expressed under β-cell 
specific promoters it results in the loss of β- and δ-cells and an increase of α- and PP- 
cells (38).  
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I.D. β-cell Dysfunction in the Development of Diabetes 
 Diabetes mellitus is a state of absolute or relative insulin deficiency.  There are 
five recognized main subtypes of diabetes: maturity of onset diabetes of the young 
(MODY), T1D, latent autoimmune diabetes of adulthood, T2D, and gestational diabetes. 
Diabetes is linked to problems in multiple physiological systems and has been 
associated with the increase in incidence of heart and kidney failure, neuropathy, lower 
limb amputations and vision loss (39). However, although the development of these 
diseases vary, β-cell dysfunction, de-differentiation, or death underlies each of these 
forms of diabetes. As such, research and therapies aimed at promoting β-cell function 
and survival are critical to promoting health in an increasingly diabetic population. From 
here, this introduction will focus on the pathogenesis of T2D.  
T2D is a chronic metabolic disorder characterized by insulin resistance in 
peripheral tissues along with β-cell dysfunction. T2D is the most dominant form of 
diabetes encompassing 80-90% of all cases. Its increase in prevalence parallels a 
concomitant increase in obesity worldwide (40). Risk factors such as genetic 
susceptibility, obesity, and insufficient physical exercise contribute to the development of 
T2D; with obesity contributing to more than 50% of cases of T2D in the world (41). 
During obesity, insulin resistance in the muscle, liver, and adipose tissue increases the 
demand for insulin secretion from the islet β-cell to maintain glucose homeostasis. In an 
attempt to keep up with the demand, the β-cell will try to compensate by producing more 
insulin and/or increasing cell mass (Figure 1) (42). During this time, blood glucose levels 
remain the same while blood insulin levels become elevated. Studies have shown a 20-
40% increase of β-cell mass in obese nondiabetic individuals (43,44). However, in 
individuals who develop T2D, this compensatory increase in β-cell mass and insulin 
production fails, leading to insulin insufficiency and frank hyperglycemia. Individuals with 
prediabetes (as diagnosed by impaired fasting glucose) have ~60% of normal β-cell  
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Figure 1: Insulin Resistance. Pancreatic β-cells secrete insulin to regulate blood 
glucose levels. Insulin triggers the uptake of glucose in the liver, muscle and adipose 
tissue. Diminishing insulin action on these tissues, result in blood glucose levels to 
increase. When insulin demand increases, the islet β-cell responds by increasing 
production and release of insulin to maintain glucose homeostasis. 
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mass and diabetic individuals have ~30-70% of normal β-cell mass (44). However, a key 
point is that insulin resistance alone is not an indication of future T2D, as only about 15-
30% of all obese (i.e. insulin resistant) individuals develop T2D (45). This finding 
suggests that insulin resistance is by itself not enough to cause diabetes and therefore 
the inability of the β-cell to fully compensate is a major determinant in the development 
of dysglycemia and frank T2D (46). Curiously, humans with T2D have also been shown 
to have a decreased volume of pancreatic mass compared to nondiabetic individuals 
(44,47). Research efforts seek to understand the mechanisms that lead from insulin 
resistance to the progression of diabetes.  
This reduction in β-cell mass in T2D resulting from increased β-cell death or 
inadequate replication and/or neogenesis increases the likelihood of hyperglycemia. This 
event places β-cells in an unfamiliar hyperglycemic environment termed glucotoxicity, 
which results in decreases in β-cell specific transcription factors such as Pdx1 and MafA, 
and decreased glucose-stimulated insulin secretion (GSIS) ultimately leading to diabetes 
(48). Restoring insulin exogenously early in T2D can reverse the dysfunctional insulin 
secretion response for at least a short period of time (49). Recent evidence points to the 
finding that individuals destined to develop T2D have β-cell dysfunction before signs of 
prediabetes (50). Diabetes research would therefore benefit from a better understanding 
the relationship between β-cell function, β-cell mass accrual, and loss of β-cell mass.  
 
Circulating Mediators of β-cell Proliferation/Replication  
Replication is one potential mechanism by which β-cells compensate for increased 
insulin demand from insulin resistance. Two fundamental concepts regarding β-cells 
have emerged over the past several years:  1) although β-cells were considered to be a 
non-replicating cell type in an adult mammal, it is now understood that they indeed 
exhibit a slow rate of replication in early adulthood, and replication declines rapidly as 
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the organism ages (51,52), and 2) the mass of β cells (and therefore the balance 
between new cell formation and death) can be dynamically altered to compensate for the 
physiologic state of the organism, as for example, following the development of insulin 
resistance (53).  A major focus of diabetes research has been the mechanisms that 
underlie postnatal β-cell growth and maintenance. Multiple studies suggest that 
replication of β cells can be triggered or enhanced in early adulthood in rodents.  Our lab 
and others (54–57) demonstrated that feeding of high fat diet to mice enhances β cell 
replication as early as 1 week following initiation of the diet.  
 Glucose has also been shown to promote β-cell replication in rodents.  Studies in 
rats with continuous 20% glucose infusion for up to 96 hours resulted in a 3-fold increase 
in β-cell mass. These results were attributed to an increase in Akt activation, however 
with no increase in proliferation (58). On the other hand, studies where 50% glucose was 
infused for 4 days demonstrated an increase in nuclear localization and protein 
translation of cell cycle promoter, cyclin D2 in mouse islets, however these studies 
showed no differences in β-cell mass, islet number, cell size or death (55). Although an 
effect of glucose to directly stimulate β-cell replication has been proposed, it is possible 
that its effect may be caused by its stimulation of insulin release from β-cells, such that 
insulin in an autocrine manner, serves as the crucial mitogen. Mice lacking the insulin 
receptor in β-cells display impaired insulin release associated with reduced β cell mass, 
whereas mice lacking the IGF-1 receptor in β cells display impaired insulin release 
without associated loss of β cell mass (59).  Interestingly, loss of both the insulin 
receptor and IGF-1 receptor in β cells results in severe reductions in β cell mass and 
frank diabetes (60). Studies ablating the intracellular signaling protein for insulin action, 
insulin receptor substrate 2 (IRS-2), showed a reduction in β-cell mass (61), whereas its 
upregulation in rat β-cells showed increased islet growth and activation of protein kinase 
B (Akt/PKB) (62). Notably, many studies have linked Akt expression to promote islet 
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growth and β-cell survival (63–65). These studies showed that overexpressing 
constitutively active Akt (caAkt) in the β-cell resulted in an increase in both β-cell size 
and islet mass (66). Other studies of mediators of PI3K signaling have supported the 
notion of Akt’s importance in β-cell proliferation. Deletion of PDK1 (3-Phosphoinositide-
dependent protein kinase 1) in mice resulted in β-cell mass reduction with insulin 
deficiency and deletion of PTEN (phosphatase with tensin homology) showed increased 
islet mass and retained cell function (67,68).  Results from these and other insulin linked 
studies suggest that insulin plays a key role and it may not be separated from the role of 
glucose, suggesting both to be main players in the β-cell expansion phenomenon.  
In addition to glucose and insulin, there are a large number of different secreted 
factors from other sources that have been evaluated for their potential critical roles in 
regulating β-cell mass, either by inducing replication and/or inhibiting apoptosis (69). 
Prolactin and growth hormone release by the pituitary gland during pregnancy also leads 
to β-cell stimulated proliferation. The release of these hormones is critical for maternal β-
cell mass expansion during pregnancy (70). Another example is the bone-derived 
hormone osteocalcin, which drives β-cell replication in a cyclin D1-dependent manner 
(71). Further studies are warranted to determine how the β-cell is able to proliferate in 
the postnatal stage under certain triggers, and how this mechanism may affect turnover 
to alleviate elevated plasma glucose.   
Lipid molecules such as free fatty acids (FFA) play many roles in cell function. For 
the β-cell, FFA are essential in glucose-stimulated insulin secretion, and its failure in 
T2D (72). Deprivation of FFA has detrimental effects on the islet; however, in chronic 
excess, in combination with excess glucose, FFAs can decrease insulin synthesis and 
secretion, and induce pathways of cellular apoptosis (73,74). It was recently discovered 
that FFAs are ligands to G-protein-coupled transmembrane receptors, such as 
GPR40/FFAR1 (75). Notably, FFAR1 is highly expressed in rodents and humans 
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(76,77). Studies of deficient mouse model of FFAR1 confirmed the role of the receptor in 
augmentation of insulin secretion, and further protection of harmful metabolic effects of 
HFD (78). However, in the same study, overexpression of the receptor resulted in liver 
steatosis, impaired islet function, and diabetes (78). As for its role in cell growth and 
replication, studies have suggested GPR40/FFAR1 mediates the action of oleate to 
promote proliferation in breast cancer cells in vitro (79). Its role in β-cell replication 
remains to be investigated. 
 
Role of β-cell Transcription Factors in β-cell Replication 
β-cell transcription factors have also been shown to play a role in β-cell replication, 
and may mediate, in part, the effect of the mitogens described above on β-cell 
replication. Perhaps the single most-important factor is Pdx1.  In mouse models 
haploinsufficient for the gene encoding Pdx1, there is impaired β-cell mass 
compensation to insulin resistance, with ensuing diabetes (80).  Similarly, humans with 
heterozygous mutations of Pdx1 develop diabetes with age, typically in adolescence or 
early adulthood (81,82).  In these individuals, it is thought that β-cell compensation for 
linear growth and/or age-related insulin resistance is impaired.  Pdx1 is crucial not only 
in the regulation of genes encoding β-cell proteins that are important in insulin secretion, 
such as the glucose transporter Glut2, glucokinase, and insulin, but also in the regulation 
of genes that are downstream of the growth-promoting insulin receptor/insulin-like 
growth factor 1 (IGF-1) receptor signaling cascade (83). Other β-cell transcription factors 
appear to play roles in β-cell replication, as well.  For example, overexpression of the 
transcription factor Pax4 (expressed in the developing pancreas) was found to increase 
β-cell replication and growth in rat islets (84). Both glucose and GLP-1 increased Pax4 
expression in both rats and human islets, however increased replication was not 
observed in the human islets (85). Another transcription factor that has recently come to 
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light as a possible inducer of replication is β-cell -specific homeodomain transcription 
factor Nkx6.1. Studies by Newgard and colleagues showed increased 3H-thymidine 
incorporation in rat and human islets that were induced to over express Nkx6.1 (86). In 
addition, a number of cell cycle genes were found in rat islets to increased their 
expression, including cyclin-D2 (84,86).  
 
I.E. Cell Cycle  
The molecular mechanisms regulating β-cell replication are governed by cell 
cycle genes and their encoded proteins (87–89). Cell division consists of two processes, 
one in charge of DNA replication and the other one in charge of segregation of 
chromosome material into daughter cells. These two processes are reflected in the 
stages of mitosis and interphase. Cells in interphase are divided into three phases: G1, S 
and G2 (90) (Figure 2). G1 is the interlude phase were the cell is preparing for DNA 
synthesis. At this stage, before committing to DNA replication, cells can enter a resting 
phase known as G0. G0 accounts for the majority of cells that are not growing and/or 
proliferating, and is thus the stage that reflects the majority of β-cells in an islet. 
Continuation of the cell cycle from G1 is followed by the S phase, where DNA replication 
occurs. G2 is the last phase in the interphase were the cell prepares for mitosis. Mitosis 
itself has different stages called prophase, metaphase, anaphase and telophase.  
Completion of cell cycle and therefore cell division occurs after all mitosis stages are 
completed and the end result is two daughter cells with the same genetic material. 
Although exceptions exist, replication of β cells is largely driven by factors that control 
the G1/S transition of the cell cycle (87). Genetic manipulation studies in mice have 
emphasized the importance of not only activators of the G1/S transition, but also of 
inhibitors, such that the balance between the two appear to regulate the overall drive for 
β-cell replication.   
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Figure 2: Cell Cycle. During interphase, the cell copies its DNA in preparation for 
mitosis. It is divided into 3 stages; G1, during this stage the cell increases protein 
synthesis in preparation to duplicate DNA; S-phase, the cell duplicates its DNA content, 
and G2, the cell resumes growth in preparation for division (mitosis). During the time the 
cell in active division, or preparation for division, it is in a fourth stage, G0, were the cell is 
in an intermediary rest (quiescent state).  
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Cell cycle regulation in β-cells has recently acquired the spotlight with emerging 
studies implicating signaling factors and pathways to an activation in replication. As 
noted above, β-cell replication in humans is at its highest during infancy and declines 
over time, such that in by age 25-30 there are few if any replicating β-cells (51,91). 
These findings are paralleled in mice, where the rate of replication declines in the weeks 
following birth (52). The mechanisms involved in β-cell replication including their capacity 
to enter cell cycle are still not fully elucidated, although the precise control of replication 
and growth in the β-cell seem to be initiated by events involving D-type cyclins and 
cyclin-dependent kinases (specifically, Cdk4 and Cdk6 in mice and humans, 
respectively) (88). Upon mitogenic stimulation, the D-type cyclins emerge to pair with the 
Cdks to form complexes that allow cell cycle entry. These complexes are considered the 
“checkpoints” to the mitogenic stimulation. One of the first roles of these complexes is to 
inactivate retinoblastoma protein (pRb), which subsequently the transcription of genes 
that promote cell cycle progression.  
 
The Role of D-Type Cyclins β-cell Replication 
There are three D-type cyclins (1, 2, and 3), and they all respond to extra-cellular 
stimulation, however they each respond differently based on the stimulation and the cell 
type; although their function is similar if not identical in activating the cell cycle 
progression (92). In human pancreatic tumor samples cyclin-D1 is highly expressed (93). 
The general consensus is that cyclin-D1 and -D2 are the most dominant types in all cell 
types across different species, leaving cyclin-D3 up for debate on its presence or 
absence in the islet β-cell. Overall, it has been well established that cyclin-D2 and Cdk4 
play an essential role in the replication of the mouse β-cell postnatally. Ccnd1 and 
Ccnd2 have been shown to increase their mRNA expression in the presence of certain 
hormones and growth factors. Prolactin (PRL) and growth hormone (GH) have been 
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shown to increase Ccnd2 expression by activation of the Janus kinase 2 (JAK2)/Signal 
Transducer and Activator of Transcription 5 (STAT5) (94) (Figure 3). Ccnd1 promoter 
activity is increased by incretins, GLP-1 and GIP (95). Suppression of Ccnd1 expression 
has been linked to pathways such as cAMP/PKA and inhibition of phosphatidylinositol 3’-
kinase (PI3K) (96). However, many other pathways have been implicated in the 
regulation of the D-type cyclins and their effects in β-cell proliferation. For example, 
Ccnd2 expression was significantly decreased in mice with β-cell specific deletion of 
calcineurin b1, implicating a signaling role for calcineurin/nuclear factor of activated T 
cells (NFAT) in the regulation of pancreatic β-cell growth (98). Many studies of the D-
type cylcins have shown that CyclinD1 and CyclinD2 are activated by distinct signals in 
rodents, however, this may not apply in the same fashion in human β-cells (99–101) .  
Deletion of Ccnd2 in mice resulted in a significant reduction in postnatal β-cell 
mass resulting in development of diabetes (102). Cyclin-D2-facilitated β-cell replication is 
activated via STAT5 pathway by GH and PRL. In vitro studies showed inhibition of 
GH/PRL-induced replication when a dominant negative (dn)STAT5 is transfected into 
the cells (94); whereas transfection with a constitutively active (ca)STAT5 showed 
increased replication and CyclinD2 expression in neonatal rat β-cells and rat INS-1 
insulinoma cells. Likewise, in vivo overexpression of dnSTAT5 in β-cells resulted in 
impairment of glucose tolerance in T2D model of high fat diet-induced obesity, whereas 
by contrast, overexpression of caSTAT5 resulted in improved glucose tolerance—due, in 
part, to increase in β-cell proliferation  (103).  Cyclin-D1 appears to have a synergistic 
effect in combination with cyclin-D2.  Loss of the gene encoding cyclin-D1 does not 
affect β-cell mass accrual during embryogenesis, but heterozygosity of the cyclin-D1 
gene in combination with homozygous loss of cyclin-D2 results in even further loss of β 
cell mass with age and severe, life-threatening diabetes (100). 
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Figure 3. Activation of Proliferation. STAT activation resulting in proliferation and 
inhibition of apoptosis has been linked with oncogenesis. Activation of certain pathways, 
such as STAT5, which with its activation forms a homodimer resulting in further 
activation of multiple pathways with the overall goal of inducing cell growth and 
downregulate programmed cell death. Figure Adapted from Diabetes Article: Human β-
cell Proliferation and Intracellular Signaling: Part 3 (97). 
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The Role of Cdks in β-cell Replication 
It was suggested over a two decades ago that the D-type cyclins, in combination 
with Cdk4, induce proliferation specifically in the β-cell (104). Knockout of Cdk4 in mice 
showed developmental defects in specific organs such as ovary, testis, and pancreas; 
resulting in infertility and reduction of islet area. The β-cells were the only endocrine cell 
affected in the pancreas by whole-body Cdk4 ablation in mice, resulting in β-cell 
deficiency with age (105). On the other hand, overexpression studies of Cdk4 showed 
islet hyperplasia mostly populated by β-cells (105). Endogenous expression of Cdk4 
rescued Cdk4 knockout animals and restored cell proliferation and normoglycemia. 
Mouse isolated islets that expressed constitutively active Cdk4 and Akt showed an 
increase in protein expression of cyclin-D1, cyclin-D2, and p21 (a major cyclin/CDK 
inhibitor) (101). This induction of cyclin-D1 and cyclin-D2 coincides with an increase in 
phosphorylation of the downstream target of Akt, glycogen synthase kinase (GSK3β) in 
the islet; inactivation of GSK3β has been shown to protect β-cells against stress-induced 
apoptosis and instability of Pdx1 (106,107). Inhibition of GSK3 induces β-cells replication 
in rat islet cells and combined with high glucose and palmitate suppresses apoptosis 
(108).   
 
Role of Cell cycle inhibitors in β-cell Replication 
Negative regulation of the cell cycle may be as important as the mechanisms 
described above for positive regulation. There are two families of cell cycle inhibitors: the 
inhibitor of kinase 4/Alternative Reading Frame (INK4/ARF) and the CDK interacting 
protein/Kinase inhibitor protein (CIP/KIP). The first family, INK4/ARF consists of p16INK4A, 
p15INK4b, p18INK4c, and p19INK4d. The second family consists of p21CIP, p27KIP, p57KIP. 
Suppression of cell cycle inhibitors may be a key in β-cell mass maintenance, as their 
involvement has been implicated in islet mass changes and pathophysiology of diabetes 
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(109). Loss of expression of p27KIP in IRS-2 and LepR knockout mice leads to a massive 
increase in number, but not in size, of β-cells. Additionally, loss of p27KIP improved the 
hyperglycemia found in these two knockout lines (109). More recent studies have shown 
that the loss of p27KIP allows for new β-cells to proliferate. p27KIP knockout mice were 
more susceptible to development of streptozotocin-induced diabetes and had greater β-
cell mass when compared to control mice. However, it seems that p27KIP has no 
influence on β-cell proliferation in neonatal stages since p27KIP knockout mice have to 
same rate of β-cell mass increase during the first three weeks after birth as wild type 
mice. Surprisingly, another CIP/KIP Cell cycle inhibitor, p21CIP, has been linked to an 
increase in β-cell proliferation, islet mass, and insulin content that leads to hypoglycemia 
in mice with the hepatocyte growth factor (HGF) or placental lactogen (mPL-1) under the 
control of the rat insulin promoter.  These transgenic animals had a marked increase of 
p21CIP expression. In human islets, adenoviral mediated transfection of CyclinD1 and 
Cdk4 resulted in upregulation of p21CIP and its translocation into the nucleus of the β-
cell. Moreover, p21CIP knockout mice had no effects on islet proliferation or glucose 
homeostasis. The lack of p21CIP expression did not result in β-cell mass growth, 
diminishing the role of this inhibitors in cell cycle progression (110,111).  
 Importantly, some of cell cycle inhibitors may be expressed at different times 
during the lifetime of the subject. p16INK4A expression is widely detectable in human islet 
samples of adult tissues compared to youth, and it seems to be the only cell cycle 
inhibitor that increases expression with aging.  Due to this unique feature, it has been 
suggested that p16INK4A is a biomarker for pancreatic islet aging. Overexpression of 
p16INK4A in mice resulted in a reduction of proliferation in the islet of younger mice but not 
in older mice. However, when β-cells deficient for p16INK4A were exposed to 
streptozotocin, they had greater rate of survival (112). These studies lead to the question 
of what role p16INK4A might have if expressed at earlier stages. It is possible that the 
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expression of p16INK4A during the aging process promotes β-cell quiescence. A quiescent 
cell, unlike senescent cell, can be stimulated into cell division at any given time, whereas 
the senescent cell is considered to be in a permanent state of growth arrest. It has been 
postulated in the field that the potential for β-cells to regenerate slows down in time, 
however, this does not mean that the cells are incapable to enter cell division under the 
right stimuli. It remains controversial as to what role aging may have in β-cell replication 
and incidence of T2D.  
 
Tumor Suppressor Genes 
Hyperplasia is the increase in volume of an organ caused by a formation of new 
normal cells. This phenomenon is observed primarily in embryogenesis, and in later life 
is primarily seen in cancer/oncogenesis (113). One gene that has been studied during 
growth abnormalities in parathyroid glands, anterior pituitary, and endocrine pancreas is 
menin. Encoded by the Men1 gene, menin is the main cause of these abnormalities, and 
the disease is known as multiple endocrine neoplasia type 1 (MEN1) (114).  
Suppression of menin in rat INS-1 insulinoma cells results in decreased insulin promoter 
activity and decreased glucose-induced insulin secretion and proliferation (115). 
Heterozygous deletion of Men1 in mice results in pancreatic hyperplasia with elevation 
of insulin and reduced blood glucose levels, in parallel with the human MEN1 phenotype 
(116), supporting the contention that both copies of this gene are necessary for normal 
suppression of replication. Islets isolated from Men1+/- heterozygous mice have 
increased BrdU incorporation, consistent with hyperproliferation (117). In addition, these 
mice had marked mRNA and protein reductions of p18INK4c, p27KIP, p15INK4b and p21CIP at 
10 months of age, whereas an increase of Cdk4 was found in their pancreatic islets 
(118). Other studies have shown that ablation of Men1 in mice accelerated the entry of 
mouse embryonic fibroblasts into S phase, an increase in Cdk2 activity, and a reduction 
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of the cell cycle inhibitors p18INK4c and p27KIP in the pancreas (119). Furthermore, this 
resulted in an increase in proliferation of the islet that leads to its enlargement with no 
effect on the exocrine region of the pancreas. Not only does menin have a role in cell 
cycle molecules, but also in molecules in the apoptotic pathway. For example, caspase 
8, a protein involved in the programmed cell death pathway, is transcriptionally 
upregulated by menin (120). Caspase 8 is induced by Fas dependent FLIP (FLICE 
inhibitory-protein) activity involved in cell death. Recent studies have suggested FLIP to 
have capability to reverse Fas signaling and induce proliferation in β-cell (119,121)  
These findings suggest that menin is a prime target for expanding β-cell replication and 
survival. Recent studies have also linked menin to gestational diabetes. During the 
gestational period, levels of menin, p18INK4c, and p27KIP fall in the maternal islet, resulting 
in β-cell mass expansion (122). All these changes seem to be due to menin regulation 
by PRL via STAT5 signaling (123). These findings, as many others described in this 
section, were performed in rodents; its role in human gestation has yet to be elucidated.  
 
Conclusions on β-cell Proliferation 
Studies in the past decade trying to explain the implications in the regulation of the 
cell cycle during β-cell maintenance and regeneration have been performed in various 
mouse genetic models and confirm the complexity of factors that regulate β-cell 
replication. So far, we know about growth factors and mitogens and their influence on D-
type cyclin expression regulation through intracellular pathways, however, how these 
pathways cross-talk and how β-cell replication can be influenced by autocrine signaling 
of insulin is still unknown.  Even though knowledge has been acquired from genetic 
mouse models, it is imperative to consider species differences in the findings when 
considering therapies for diabetes in humans. For example, it has been shown that it is 
possible to induce regeneration of β-cells in rodents after partial pancreatectomy, duct 
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ligation, or HFD feeding, however this has not been observed in human adults 
(124,125).  
 
I.F. Regulation of mRNA Translation in the β-cell 
 The rapid adjustment of protein levels in response to mitogens can be most 
efficiently accomplished at the level of mRNA translation. The translation of mRNA by 
ribosomes can be separated into three major stages: initiation, elongation, and 
termination (Figure 4). In the mammalian cell, distinct initiation, elongation, and 
termination factors are responsible for the orderly progression of these processes, and 
deficiency of deletion of these factors can have profound effects on global protein 
synthesis (126).  Regulation of mRNA translation primarily occurs during either initiation 
or elongation phases. In eukaryotes, there are a number of different initiation and 
elongation factors that serve as regulators of these processes, and many of these 
factors can be controlled by posttranslational modifications, such as phosphorylation. 
Control of translation is governed by two major signaling pathways. One major signaling 
pathway regulating translation in response to extracellular signals and availability of 
amino acids includes kinases such as phosphoinositide 3-kinase (PI3K), 
phosphoinositide-dependent protein kinase 1 (PDK1), Akt, and mammalian target of 
rapamycin (mTOR) (127). mTOR phosphorylates the inhibitory eIF4E binding proteins, 
which in turn release the inhibitory control over eIF4E allowing initiation to occur. In 
addition, mTOR facilitates translation of transcripts of elongation proteins such as eEF1A 
and eEF2, mRNA-binding protein PABP, and ribosomal protein S6 to increase 
translation capability of the cell (127). A second major mechanism for regulating 
translation is via the eukaryotic initiation factor 2-α (eIF2-α). Phosphorylation of eIF2-α is 
the result of stress sensing by kinases such as protein kinase RNA-like endoplasmic 
reticulum kinase (PERK), protein kinase R (PKR), general control non-derepressible 2  
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Figure 4: Mechanism of Eukaryotic Translation. Coordinated processes of initiation, 
elongation and termination, take place through to facilitate eukaryotic translation. This 
initiation process requires mRNA, ribosomal subunits, eIFs, and Met-tRNA, to initiate the 
process of protein synthesis at the start codon. The elongation process requires 
ribosome subunits, eRFs, mRNA and aminoacyl tRNAs, to polymerize the growing 
peptide. The termination process requires mRNA, eRFs and ribosomal subunits, to 
release the protein for processing and activity. Lastly ribosomal subunits and translation 
factors are released for recycling and to commence the process with a new transcript.  
 
 
 24
(GCN2) and heme-regulated inhibitor (HRI) (128). Each of these kinases are regulated 
by different intra/extracellular stress signals, including unfolded proteins in the ER 
lumen, viral infection, heme deficiency and amino acid starvation (129–131). All these 
molecules converge in the phosphorylation of residue S51 of eIF2-α, collectively known 
as the integrated stress response (ISR). Translation of these mRNAs is critical for 
mitigation of stress and activation of proliferative responses in response to extracellular 
signals.   
 
The Roles of Polyamines, Deoxyhypusine Synthase (DHS), and eIF5A in mRNA 
Translation 
Whereas most of the translation initiation and elongation factors described to 
date are “general” translational factors—that is, they are required for the translation of all 
mRNAs—few have been described that function to facilitate translation of only subsets 
of mRNAs (Figure 4).  Such translational factors therefore represent prime candidates 
for the selective responses (e.g. proliferation) of cells to intra- and extracellular signals.  
Polyamines are ubiquitous small molecules that may have potential roles in many 
heritable human diseases (132). The polyamines found in mammalian cells are 
putrescine, spermidine and spermine. These molecules form as the result of consecutive 
enzymatic reactions that begin with the action of arginase on arginine to form ornithine.  
Ornithine decarboxylase (ODC) is the rate-limiting enzyme of polyamine biosynthesis 
that converts ornithine to putrescine (133). The levels of ODC are dynamically and 
rapidly altered based on the replication state of the cells, with higher levels seen during 
cellular replication (134). Many physiological processes that require rapid growth such 
as tissue regeneration, hormonal stimulation and differentiation enhance the activity of 
ODC and polyamine biosynthesis. The significance of polyamines arises from their role 
in cellular replication, as depletion of polyamines (via inhibition of ODC) results in loss in 
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replication (135). Precisely how polyamines contribute to replication is not entirely clear, 
although it has been suggested that they function to stabilize the DNA replication fork 
during S phase (136). A more provocative role for polyamines, specifically spermidine, is 
their role in the activation of the translational factor eukaryotic translation initiation factor 
5A (eIF5A). 
eIF5A is a small acidic protein (~17kDa), that is highly conserved from 
archaebacteria to mammals, and is essential for cell viability (137). eIF5A was initially 
identified as a translation initiation factor due to its ability to stimulate methionyl-
puromycin synthesis, although since its naming it is thought to function primarily as a 
translational elongation factor (138). Depletion of eIF5A in yeast results in a 30% 
decrease in overall protein synthesis rate, accumulation of “stalled” polyribosomes on 
nascent mRNAs, and in prolonged ribosomal transit times (139).  Although studies of a 
yeast temperature-sensitive mutant of eIF5A showed a smaller effect on protein 
synthesis. On the other hand, in unstressed mammalian cells, depletion of eIF5A results 
in only a 5% reduction of mRNA translation elongation (140). These results argue 
against a role for eIF5A as a general translation factor, but instead suggest a more 
restricted role in the translation of a subset of mRNAs. Mechanistic studies in yeast have 
shown that eIF5A has the capacity to bind a preferential mRNA nucleotide sequence 
encoding consecutive proline residues and cellular target mRNAs, and that eIF5A 
catalyzes read-through translation of poly-proline containing proteins (141). These 
studies propose eIF5A, when in the proximity of the E site of the ribosome, stimulates 
peptidyl-transferase activity of the ribosome facilitating translation of poor substrates 
such as those containing consecutive proline residues. Furthermore, in agreement with 
the hypothesis that eIF5A works in translation control eIF5A mutant studies 
demonstrated that eIF5A specifically binds to actively translating ribosomes, more 
specifically to the 80S ribosome (142,143).   However, exactly how this binding with 
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ribosomes occurs and/or if it occurs via protein-RNA interactions remains largely 
unknown. Our lab found that in the presence of cytokines, eIF5A facilitated the 
translation of Nos2 in β-cells in a stress responsive manner by directly binding to the 
Nos2 mRNA in the nucleus, and helping to facilitate its movement to cytoplasm of the β-
cell for translation (144). 
eIF5A is unique because it is the only protein to undergo a posttranslational 
modification dependent on the polyamine pathway, called hypusination (145). 
Hydroxyputrescine-lysine (a.k.a “hypusine”) is formed during a posttranslational reaction 
in which a moiety of spermidine is transferred to the amino group of Lys50 of eIF5A 
(146) (Figure 5).  This posttranslational modification essential for eIF5A’s known role in 
translation. Hypusination is catalyzed by the enzyme deoxyhypusine synthase (DHS). 
Hypusination occurs in two steps:  1) DHS transfers a 4-aminobutyl moiety from 
spermidine to the ε-amino group of Lys50 (K50) in mammalian cells (147) to form a 
deoxyhypusine intermediate, 2) deoxyhypusine hydroxylase (DHH) hydroxylates the 
deoxyhypusine intermediate to form the hypusine-containing mature eIF5A. In yeast, 
mutations in the K50 residue of eIF5A results in blockade of hypusination (148,149). 
Additionally, when either DHS or DHH are inhibited via small molecule inhibitors, 
mammalian cell growth (proliferation) is halted (150–153). DHS can be chemically 
inhibited by N1-Guanyl-1,7-Diaminoheptane (GC7) (154,155). DHS inhibition studies 
have shown to not only disrupt the initial step of eIF5A maturation but also control 
protein biosynthesis and cell proliferation (154). An in vivo approach into evaluating the 
absence of DHS activity, studies targeting Dhps gene to be deleted in progeny resulted 
in a lack of Dhps-/- embryos (156–158). A study conducted in our lab showed DHS 
deletion to be embryonic lethal (156). Similarly, mouse model deletion of eIF5A resulted 
in embryonic lethality (157). Studies of homozygous deletion of eIF5A in blastocysts 
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showed growth defects as early as embryonic day 3.5 when compared to heterozygous 
or wild type blastocysts (157). 
 
 
Figure 5: Hypusination of eIF5A. Two enzymes encompass the hypusination of eIF5A; 
deoxyhypusine synthase (DHS) and deoxyhypusine hydroxylase (DOHH). These 
enzymes act in sequence to form a hypusine residue at the lysine 50 of eIF5A.  
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Recent studies have approached another mouse model to evaluate this pathway. The 
conditional knockout of Dohh (159) was also deemed embryonic lethal, and blastocyst 
evaluation concluded that lethality occurs before embryonic day 9.5 (159). These studies 
emphasize the roles of Dhps, Dohh, and Eif5a in embryonic development, but their 
embryonic lethality preclude an assessment of the role of these factors in cellular 
replication.  
 
I.G. Conclusion and Hypothesis 
Over 8.5% of the world population has T2D, and it is estimated that by 2030 it will 
be the 7th leading cause of death in the world (160). While a major genetic basis exists 
for the development of diabetes, the recent surge in prevalence underscores the 
influence of lifestyle, environmental, and technological factors in contributing the 
diagnosis and prevalence of the disease. While increasing β-cell mass by proliferation 
appears to have a beneficial effect in T2D, there is no direct way to only induce 
proliferation in a particular cell population such as the β-cell. Ideally, an increase in β-cell 
mass would normalize blood glucose levels, improve insulin serum concentration, or 
alleviate the insulin demand in a small population of β-cells. However, a therapy that 
induces proliferation specifically can lead to further complications such as producing 
tumors leading to complications harder to treat than T2D.    
Based on the studies presented above and the gap in the understanding of 
translational mechanisms leading to compensation and proliferation in the β-cell, my 
dissertation research will test the hypothesis that hypusinated eIF5A is required for the 
compensatory proliferation of the islet β-cell during the early phase of insulin resistance. 
Furthermore, I predict that hypusinated eIF5A allows for proliferation in the β-cell by 
regulating the translation of cell cycle molecules important for transition between the 
G1/S phase. Using cell-based approaches and a conditional DHS knockout mouse 
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model, I tested my central hypothesis by pursuing the following aims: 1) Assess the role 
of β cell death and proliferation during the development of glucose intolerance in 
response to high fat diet (HFD) feeding in mice, 2) Assess the role of DHS in the β-cell in 
mice fed a normal chow diet, and 3) Delineate cellular and metabolic consequences of 
DHS deficiency under increased metabolic demand when mice are fed a HFD.  
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Chapter II  
Research Design and Methods 
 
Animal Studies. Animals were maintained under pathogen-free conditions 
according to protocols approved by the Indiana University School of Medicine 
Institutional Animal Care and Use Committee. For Dhps knockout studies, mice 
containing the Dhps floxed alleles (Dhpsfl/fl) were crossed to previously described MIP1-
CreERT mice to generate β-cell-specific Dhps knockout mice (DhpsΔβ)  on a C57BL6 
genetic background (161). Male mice were utilized for all experiments due to the gender 
bias found previously in many studies with Non-diabetic (NOD), Zucker Diabetic rats and 
others (162). In addition, it has been suggested that in some cases there are different 
effects of sex hormones, for example, being protective in the females as to not develop 
hyperglycemia in the same rate as males. Male mice with desired genotype were then 
weaned and utilized for all the experiments in this study. To induce genetic knockout, 
mice were administered three weekly intraperitoneal injections of tamoxifen (5mg) 
dissolved in peanut oil beginning at 8 weeks of age. One week following the final 
tamoxifen injection, mice were placed on either a normal chow diet (16% kcal from fat) 
or high fat diet (60% kcal from fat; Research Diets; D12492). Lean body mass and fat 
mass were obtained via dual-energy x-ray absorptiometry (DXA) using a Lunar 
PIXImus2 Densitometer (GE Medical Systems). 
For studies involving measurement of β-cell death, male C57BL/6J mice, male 
C57BL/KsJ-db/db, and male C57BL/KsJ-db/+ mice were obtained from the Jackson 
Laboratories. C57BL/6J mice were acclimated for 1 week prior to being placed on either 
a low fat diet (10% kcal from fat, Research Diets; D12450B) or high fat diet (60% kcal 
from fat; Research Diets; D12492) starting at 8 weeks of age. C57BL/KsJ-db/db, and 
C57BL/KsJ-db/+ mice were feed a regular chow diet (Research Diets; 5008). Blood was 
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harvested from the tail vein and processed as serum for the differentially-methylated 
DNA (DMD) assay. All mice were monitored for body weight and random blood glucose 
via tail vein weekly. C57BL/6J mice underwent a glucose tolerance test (as described 
below). A subset of C57BL/6J mice from each group was euthanized biweekly and 
pancreata were harvested for β-cell mass measurements. After 10 weeks of diet, a 
subset of C57BL6/J mice received intraperitoneal injections of streptozocin (STZ) at a 
dose of 55 mg/kg body weight daily for 5 days.  
 
Intraperitoneal Glucose Tolerance Test (IPGTT). Mice from all strain backgrounds 
were fasted overnight (~16 hours). Mice were then injected intraperitoneally with 2 g/kg 
body weight of D-glucose (individually-dosed) at time 0 and blood was obtained via tail 
collection at 0, 10, 20, 30, 60, 90, and 120 minutes post-injection of glucose. Blood 
glucose was analyzed using the Abbott Animal Health AlphaTRAK blood glucose meter 
(Abbott Laboratories, Abbott Park, IL). 
 
Glucose-stimulated insulin secretion measurements in vivo. Mouse islets were 
isolated as described below. About ~50 islets per mouse were utilized to performed 
glucose-stimulated insulin secretion (GSIS) as described previously (163). Islets were 
incubated briefly in secretion assay (SAB) buffer containing 2.5 mM glucose for an hour, 
and then 15 mM glucose for another hour. Supernatants were collected and assayed 
using radioimmunometric assay for insulin for insulin (ALPCO); values were normalized 
to total protein content of the islet fraction.  
 
Pancreatic Islet Isolation. Pancreatic islets were isolated from mice by 
collagenase digestion by the Diabetes Center Islet Core (164). Pancreata were inflated 
with 2.0 ml of collagenase/protease mixture (Collagenase (CIzyme MA) and Neutral 
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Protease (CIzyme BP)). Pancreata were then incubated at 37 °C for 15 min. Pancreata 
were dissociated with a series of Hank’s Balanced Salt Solution (HBSS) and Bovine 
Serum Albumin (BSA) solutions and centrifugation and filtering steps. Islets were hand-
picked, and cultured in phenol-free low-glucose Dulbecco's modified Eagle's medium 
prior to use. Islets were picked by hand and counted, and allowed to recover for a short 
period of time in 11mM glucose RPMI before experimentation. 
 
 Insulin ELISA. Upon euthanasia, blood was collected from mice by cardiac 
puncture in the fed state. Plasma was obtained by centrifuging blood samples at 4°C for 
10 minutes at 2000 x g using a tabletop centrifuge. Plasma insulin concentrations were 
determined using the Mouse Ultrasensitive Insulin ELISA kit (ALPCO, Salem, NH). 
 
DNA isolation and bisulfite conversion. DNA was extracted from mouse blood 
using a genomic DNA extraction kit (Sigma-Aldrich, St. Louis, Missouri). DNA was 
isolated from 20-50 μl of serum or cellular supernatant using QIAamp DNA Blood Mini 
Kit (Qiagen) with 5 μg poly-A as a carrier. DNA recovery (of the poly-A carrier) was 
quantified using a nanophotometer (Implen). All samples showed ≥85% recovery of DNA 
following isolation. Samples then underwent bisulfite conversion using the EZ DNA 
Methylation kit or the EZ DNA Methylation-Lightning kit (Zymo Research), and 
conversion was verified using a pre- and postconversion sample in the ddPCR. 
 
Differentially-methylated DNA (DMD) assay. Primers and dual-fluorescent probes 
were used for interrogating methylation at CpG position -182 at the mouse Ins2 gene. 
The ddPCR assay was run on bisulfite-treated DNA from each sample in triplicate using 
a custom designed dual-fluorescent probe-based multiplex assay (AHMSN8K; Life 
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Technologies, Gaithersburg, Maryland). For amplification of the mouse 2 PPI promoter, 
the following primers were used: 5′-
AATTGGTTTATTAGGTTATTAGGGTTTTTTGTTAAGATTTTA-3′ (forward); 5′-
ACTAAAACTACAATTTCCAAACACTTCCCTAA-3′ (reverse). The following probes were 
used: 5′-CTCATTAAACGTCAACACC-3′ (VIC); 5′-CTCATTAAACATCAACACC-3′ 
(FAM). PCRs were performed using TaqMan® Universal PCR Master Mix, No 
AmpErase UNG (Life Technologies) with 60 amplification cycles at 92°C for 15 seconds 
followed by 60°C for 90 seconds. Water was run as a negative control for all reactions. 
Amplified products were subcloned into the T/A cloning vector pCR2.1 (Invitrogen, 
Carlsbad, California), and a minimum of 10 clones were sequenced to confirm the 
identity of the PCR products. DdPCR was performed using ddPCR Supermix for Probes 
(Bio-Rad) with the following cycling conditions: 95°C for 10 min, 94°C for 30 s, and 
57.5°C for 60 s for 40 cycles. Droplets were analyzed by a QX200 Droplet Reader and 
QuantaSoft Software (Bio-Rad), from which a concentration (copies/µL) of methylated 
and unmethylated Ins2 DNA was obtained. This final concentration was extrapolated to 
copy per microliter of serum and then log-transformed for parametric statistical analysis. 
 
 Morphometric assessment of β-cell mass. Pancreata from at least five different 
mice per group were fixed in 4% paraformaldehyde, paraffin embedded, and sectioned 
onto glass slides. Pancreata from 3 mice per treatment group were rapidly dissected and 
weighed, fixed in 4% paraformaldehyde, paraffin-embedded, and longitudinally 
sectioned. Three sections per pancreas (approximately 100 μm apart) were 
subsequently immunostained for insulin and counterstained with hematoxylin (165), and 
digital images were acquired on an Axio-Observer Z1 microscope (Zeiss) fitted with an 
AxioCam high resolution color camera. β-cell area fraction (calculated using Axio-Vision 
Software) was multiplied by pancreatic weight to obtain β-cell mass. Data represent the 
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average from 3 sections per pancreas, and 3 pancreata from each treatment group. The 
β-cell mass was then calculated by multiplying the relative β-cell volume by the 
corrected pancreatic weight. Pancreata were immunostained for cellular 
proliferation/morphology changes using the following antibodies: anti-insulin (A0564, 
Dako, 1:1500), anti-glucagon, (PU039-UP, Biogenex, 1:100), ApopTag® Red In Situ 
Apoptosis Detection Kit (EMD Millipore), and nuclei were stained with Hoechst 33342, 
(Life Technologies).  
 
 Immunohistochemistry, immunofluorescence, and Immunoblots. 
Immunohistochemistry of pancreas sections were performed using anti-insulin 
antibodies (sc-9168 [Santa Cruz Biotechnology]; 1:250) and horseradish peroxidase-
conjugated secondary antibodies (Vector Laboratories). For immunofluorescence of 
pancreas sections, sections were stained with anti-hypusine eIF5A (1:100), anti-PCNA 
(PC10, ab29 [Abcam]; 1:200), anti-Glucagon antibody (sc-514592 [Santa Cruz 
Biotechnology]; 1:200), anti-DHS antibody (sc-376580 [Santa Cruz Biotechnology]; 
1:200), anti-DHS antibody (ABCENT1350120 [Advanced Biochemicals (ABC)]; 1:200), 
and/or anti-insulin antibodies (Life Technologies; 1:250). Alexa Fluor 568–donkey anti-
rabbit antibody, Alexa Fluor 488–donkey anti-guinea pig antibody and Alexa Fluor 647-
donkey anti-rabbit antibody were used as secondary antibodies (Invitrogen). Images 
were acquired using a Panoramic MIDI (3DHistech) 
 Whole-cell extracts from rodent islets and MIN6 β-cells were collected in lysis 
buffer containing 10% glycerol, 0.1% NP-40, 0.05% deoxycholate, 50mM Tris-HCL, 
10mM NaF, 1mM EDTA, and 1mM DTT and supplemented with protease and 
phosphatase inhibitors (Roche). Cell extracts were analyzed via immunoblot by 
performing separation of 15-20 µg of protein extract by 4-20% gradient SDS-PAGE 
(Invitrogen). Protein was transferred to a fluorescence compatible PVDF membrane 
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(Millipore) using a wet transfer apparatus (BioRad). Membranes were blocked with 
Odyssey blocking buffer (LiCor Biosciences), and incubated overnight at 4°C with 
primary antibodies of anti-CyclinD2 (D52F9 [Cell Signaling]), anti-DHS antibody 
(ABCENT1350120 [Advanced Biochemicals (ABC)], anti-actin (691001 [ImmunO]), anti-
Total eIF5A(sc 18939 [Santa Cruz Biotechnology]), anti-hypusine (21st Century 
Biochemicals) (166), anti-PCNA (PC10, ab29 [Abcam]), anti-tubulin (sc-8035 [Santa 
Cruz Biotechnology]), and anti- ERK1/2 (sc-292838 [Santa Cruz Biotechnology]). 
Immunoblots were then washed with 0.05% Tween 20 in PBS, incubated with 
fluorophore labeled secondary antibodies for 1h at RT, and washed with PBS. 
Immunoblots were visualized and blot intensity quantified by using the LiCor Odyssey 
system (LiCor Biosciences).  
 
 Polyribosome Profile (PRP) analysis and RT-PCR. PRP experiments using 
isolated murine islets were conducted as previously described (Hatanaka et al., 2014; 
Templin et al., 2014). Islets were washed twice with cold PBS containing 50 µg/ml 
cycloheximide (CHX, Sigma-Aldrich). Islets were harvested in 500µl of lysis buffer 
containing 20mM Tris-HCL (pH7.5), 10mM MgCl2, 100mM NaCl, 1% Triton X-100, 
50U/mL recombinant ribonuclease inhibitor RNasin (Promega), and 50 µg/ml CHX. The 
cell lysates were passed through a 23-gauge needle and incubated on ice for 10 min, 
followed by centrifugation at 13,000 x g for 10 min at 4 °C. A portion of the lysate 
supernatant was preserved as the input sample to determine total mRNA levels. 
Supernantant (400 µl) was then added onto a 10–50% sucrose gradient solution 
containing 20mM Tris-HCL (pH 7.5), 5mM MgCl2, 100mM NaCl, and 50 µg/ml CHX. The 
gradients were centrifuged at 4 °C in an ultracentrifuge at 288,000 x g for 2h (Beckman 
SW-41Ti rotor). A piston fractionator (BioComp Instruments, Fredericton, New 
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Brunswick, Canada) was used to fractionate the gradients, and absorbance of RNA at 
254 nm was recorded using an in-line UV monitor (BioRad). The eluate was collected 
using a fraction collector, and total RNA from the fractions was reverse transcribed and 
subjected to quantitative RT-PCR. Polyribosome-to-monoribosome (P/M) ratios were 
quantitated by calculating the AUC corresponding to the polyribosome peaks (more than 
two ribosomes) divided by the area under the curve for the monoribosome (80S) peak. 
Reverse-transcribed RNA was analyzed by real-time PCR using SYBR Green I-based 
methodology as described in the RNA isolation below (167). The following primer sets 
were used for : Cyclin D2, 5’-GCTATGGAGCTGCTGTGCT-3’ (forward) and  5’- 
CCAAGAAACGGTCCAGGTAA-3’ (reverse) ; Cyclin D1, 5’-
GCGTACCCTGACACCAATC-3’ (forward), 5’- CACAACTTCTCGGCAGTCAA-3’ 
(reverse); Cyclin D3, 5’- GGAAGCTATGGACCAGCAAG -3’ (forward), 5’- 
TTTGCACGCACTGGAAGTAG -3’ (reverse); Cyclin A2, 5’- 
TCCTTGCTTTTGACTTGGCT -3’ (forward), 5’- ATGACTCAGGCCAGCTCTGT -3’ 
(reverse); Cyclin E1, 5’- GCTTCTAGACCTGTGCGTCC -3’ (forward), 5’- 
CTTTCTTTGCTTGGGCTTTG -3’ (reverse); Cyclin G1, 5’- 
AGGTCTGCGGCTTGAAACTA -3’ (forward), 5’- ATTCGGATCAAATCAGTCGC -3’ 
(reverse); CDK2, 5’- GTTGACGGGAGAAGTTGTGG -3’ (forward), 5’- 
TGATGAGGGGAAGAGGAATG -3’ (reverse); CDK4, 5’- TATGAACCCGTGGCTGAAAT 
-3’ (forward), 5’- CCTTGATGTCCCGATCAGTT -3’ (reverse); CDK6, 5’- 
GCCTATGGGAAGGTGTTCAA -3’ (forward), 5’- GGGCTCTGGAACTTTATCCA -3’ 
(reverse); p18, , 5’- AATGGATTTGGGAGAACTGC -3’ (forward), 5’- 
TGACAGCAAAACCAGTTCCA -3’ (reverse); p21, 5’- TCCAGACATTCAGAGCCACA -3’ 
(forward), 5’- GACCCAGGGCTCAGGTAGA -3’ (reverse); p27, 5’- 
GATACGAGTGGCAGGAGGTG -3’ (forward), 5’- TTCTGTTCTGTTGGCCCTTT -3’ 
(reverse); p57, 5’- CACTCTGTACCATGTGCAAGGAGTA -3’ (forward), 5’- 
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TTTCTCTTTTTGTTTTGCACTGAGA -3’ (reverse); Menin, 5’- 
TTCAGCTTCATCACAGGCAC -3’ (forward), 5’- ACCACCCAAGCATGATCTTC -3’ 
(reverse); Ki67, 5’- CTGCCTGCGAAGAGAGCATC -3’ (forward), 5’- 
AGCTCCACTTCGCCTTTTGG -3’ (reverse); PCNA, 5’- ACCTGCAGAGCATGGACTCG 
-3’ (forward), 5’- GCAGCGGTATGTGTCGAAGC -3’ (reverse); INS1, 5’- 
ACCTTTGTGGTCCTCACCTG -3’ (forward), 5’- AGCTCCAGTTGTGGCACTTG -3’ 
(reverse); INS2, 5’- TGTGGTTCTCACTTGGTGGA -3’ (forward), 5’- 
CTCCAGTTGTGCCACTTGTG -3’ (reverse); PDX1, 5’- CTCCGGACATCTCCCCATAC -
3’ (forward), 5’- ACGGGTCCTCTTGTTTTCCT -3’ (reverse); GK, 5’- 
AAACTACCCCTGGGCTTCAC -3’ (forward), 5’- CCACGATGTTGTTCCCTTCT -3’ 
(reverse); GLUT2, 5’- GGCACAGACACCCCACTTAC -3’ (forward), 5’- 
GCCAACATTGCTTTGATCCT -3’ (reverse); and Actin, 5’- 
AGCCATGTACGTAGCCATCC -3’ (forward), 5’- CTCTCAGCTGTGGTGGTGAA -3’ 
(reverse). Samples were reported as the percent of total recovered RNA. Samples 
utilized for real-time RT-PCR had approximately 106 cells or 50-100 islets isolated in 350 
ml of Buffer RLT (Qiagen) containing 1% β-mercaptoethanol. Samples were then 
sheared through a 27-gauge needle, and RNA isolation was processed as described 
below. All data represent the mean of triplicate determinations from at least three 
independent experiments of MIN6 cells or pooled mouse islets from three separate 
isolations.   
 
RNA isolation and analyses. MIN6 β-cells and isolated murine islets were lysed 
using Qiagen Buffer RLT with 1% β-Mercaptoethanol and RNA was isolated using an 
RNeasy mini kit (Qiagen). Purified RNA was reverse-transcribed using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems). Reactions were performed in a 
96-well plate using the Mastercycler Nexus Gradient (Eppendorf). Each reaction 
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contained the following: 0.75 µl of SYBR GREEN (Applied Biosystems), 10 pmol/µl 
Primer mix, 3 µL of cDNA, and RNase free water to a total volume of 25 µl. The PCR 
conditions used were 95°C for 15 min, followed by 40 cycles of 95°C for 15 s, 60°C for 
40 s. Cycle threshold values were obtained and normalized to Actin. The ∆∆Ct method 
was used to determine relative expression levels (168). RNA from isolated islets was 
sent to the Center for Medical Genomics Core in IU School of Medicine for RNA deep-
sequencing analysis.  
 
Cell Isolation and Culture. MIN6 β-cells were maintained in 25 mM glucose. 
Mouse islets were cultured in 11 mM glucose and were allowed to recover for one hour 
prior to experimentation. On the evening prior to experimentation, cells were incubated 
in medium containing 5.5 mM glucose, and on the morning of experimentation, glucose 
concentration was increased to 20 mM.  For PRP experiments, islets were transferred 
into cold RPMI medium containing 5 mM glucose after isolation and used immediately. 
Sodium palmitate, sodium oleate, and fatty acid–free BSA, were purchased from Sigma-
Aldrich. Free fatty acid (FFA) and fatty acid–free BSA conjugates (at an 8:1 molar ratio 
of FFA to BSA, unless otherwise stated) were prepared as described 
previously (Listenberger et al., 2001). Control cells were treated identically in terms of 
glucose concentrations, except that BSA was added without FFA. Protein samples were 
then submitted for Reverse Phase Protein Array (RPPA) at the University of Texas 
Anderson Center for profiling. 
  
RNA Immunoprecipitation (RIP). RIP assays from 1 × 107 formaldehyde cross-
linked MIN6 cells were performed using the Magna RIP RNA-Binding Protein 
Immunoprecipitation Kit (EMDMillipore). All steps in the protocol were followed with the 
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exception of reversal of cross-linking, which required a 2-hour incubation at 65 ºC. 
Isotype-matched antibodies against eIF5A and the FLAG-Ctl epitope (for control 
immunoprecipitations) were used at a final dilution of 1:100. Immunoprecipitated RNA 
was reverse-transcribed and subjected to real-time PCR amplification for selected 
genes, as described above. All data represent the average of triplicate determinations 
from at least 3 independent RIP assays. 
 
 Statistical Analysis. All data are presented as mean ±SEM. For comparisons of 
methylated and unmethylated mouse Ins2 DNA levels, a two-tailed unpaired Student’s t 
test was used. For analysis of methylated and unmethylated INS DNA levels, a Kruskal-
Wallis (non-parametric) test was employed followed by a Dunnett’s post-test (to compare 
values to healthy controls). Statistical significance was assumed at P<0.05. 
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Chapter III 
Transient β-cell Death during Obesity and Glucose Intolerance 
 
In this chapter, I explore the possibility of β-cell death under high fat diet feeding in mice 
by measuring a circulating biomarker. Experiments with mice were carried out in 
collaboration with Eli Lilly Co. scientists in the Diabetes department. 
 
III.A. Introduction 
The demand on insulin production and secretion is increased in the presence 
peripheral-tissue insulin resistance, as seen in the setting of high fat diets (HFDs) (169). 
During HFD feeding, a major factor in the progression from normoglycemia to 
hyperglycemia is the inability of the β-cell to fully compensate for peripheral tissue insulin 
demands (170–173). At least two mechanisms exist to account for insufficient insulin 
secretion:  reduction in β-cell function or a reduction in β-cell mass (or both).  Islets 
isolated from humans and rodents with type 2 diabetes (T2D) suggest that β-cell 
dysfunction (as measured by insulin release in response to a glucose challenge of islets 
in vitro) occurs (174–176).  Evidence for reduced β-cell mass also exists.  For example, 
cross-sectional studies in humans using autopsy specimens have shown that β-cell 
mass is reduced in individuals with type 2 diabetes (T2D) compared to obese or lean 
non-diabetic individuals (177,178). Together, these findings suggest that a combination 
of reduced function and mass of β-cells contribute to the observed lack of insulin 
secretory capacity in T2D.  
Genome-wide associated studies support the idea of variants in genes that 
regulate β-cell function and development contribute to the risk of β-cell dysfunction in the 
setting of T2D (179). However, the precise mechanism(s) accounting for the reduction in 
β-cell mass in T2D remain elusive. Because studies of β-cell mass in humans emanate 
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from cross-sectional autopsy specimens, it remains possible that the observed reduction 
in β-cell mass pre-existed in these individuals and did not reflect a dynamic change. 
Nevertheless, a working hypothesis in the field is that dynamic loss of β-cells via death 
or de-differentiation accounts for the progression to T2D. Cadaveric donor studies have 
shown that β-cell loss could be the result of β-cell apoptosis (177), whereas other 
studies have suggested dedifferentiation as a key mechanism for β-cell loss in mice and 
humans (180,181).  
 Our lab and other groups have established an assay that measures circulating 
unmethylated DNA encoding preproinsulin as a biomarker of β-cell death (182–184). β-
cells have a higher frequency of unmethylated CpG residues in the DNA encoding 
preproinsulin compared to other cell types (185). Upon death, the β-cell releases its DNA 
into the circulation, and its detection in the circulation is evidence of β-cell death. The 
differentially-methylated DNA (DMD) assay is the technique proposed as a method of 
measuring β-cell death in vivo (184,186–189). The DMD assay, performed on bisulfite-
treated DNA (to convert unmethylated cytosines to uracils), utilizes a single-nucleotide 
polymorphism discrimination PCR-based technique (TaqMan® probes) to detect the 
presence or absence of cytosine methylation at a given CpG site (182,184). In this 
respect, the assay discriminates species of DNA liberated from dying β-cells 
(unmethylated CpG) and DNA liberated from dying non- β-cells (methylated CpG).  
 Multiple different DMD assays to detect β-cell death have been described (182–
184,189,190). The assays differ with respect to the particular CpG site being detected 
and the technique by which it is measured.  The assay developed and utilized by our 
group assesses the methylation status of the CpG site at position -182 bp relative to the 
start site of the mouse Ins2 gene (184).  The assay detects β-cell death in the circulation 
in mice following streptozotocin (STZ) treatment and prior to the occurrence of diabetes 
in type 1 diabetic non-obese diabetic (NOD) mice (184). A limitation of these prior 
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studies was that real-time PCR provided only relative quantitation of DNA; instead, 
knowing absolute levels of DNA (as in copy numbers per unit volume) might allow for 
more precise and sensitivity determination of the magnitude of β-cell loss.  Recently, our 
group and others have employed digital PCR (ddPCR), a technique that provides 
absolute quantitation of DNA fragments, requires only microliter quantities of serum from 
fresh or banked samples, and shows greater sensitivity than traditional quantitative PCR 
(191,192).  DdPCR technology involves the use of conventional TaqMan® assays and a 
microfluidics-based partitioning of a PCR reaction into 10K-20K droplets.  Following 
thermal cycling of the partitioned reaction, the droplets are analyzed by a flow cytometer 
to identify those with positive and negative signals.  Poisson statistics is used to 
calculate absolute quantities (copy numbers) of each DNA species (193).  The DMD 
assay coupled to ddPCR technology has yet to be applied to assess β-cell death in the 
T2D disease progression. The studies in this chapter utilize the DMD assay (with dPCR) 
in C57BL/6J mice fed a HFD compared to control mice on a low-fat diet (LFD), and in 
diabetic C57BLKs/J-db/db mice compared to control db/+ mice.  My results suggest that 
β-cell death occurs in an episodic, rather than continuous, fashion during the course of 
obesity. 
 
III.B. Results 
β-cell death DNA assay development.  
 To assess β-cell death in mouse models of obesity and T2D, I modified our 
established real-time PCR-based DMD assay (184) for compatibility with the more 
sensitive and specific ddPCR technique that allows for absolute quantitation of DNA 
copy numbers. The primers described in that study interrogated differential methylation 
of cytosine at position –182 bp (relative to the transcriptional start site) of the mouse Ins2 
gene. I validated the specificity of these primers in ddPCR using plasmids containing 
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cloned methylated or unmethylated Ins2 gene. As shown in the 2-dimensional ddPCR 
plots in Figure 6A, the primers quantitatively distinguished mixtures of these plasmids. 
Figure 6B-D shows that the primers linearly and quantitatively detected mouse islet DNA 
spiked into mouse serum. I then applied this DMD assay to a mouse model of obesity 
and impaired glucose tolerance (IGT) and to a mouse model of T2D, both followed 
longitudinally. 
 
Glucose intolerance in mice after HFD feeding for several weeks 
 To determine how obesity affects glucose homeostasis, β-cell compensation, and 
β-cell death, I treated male C57BL/6J mice with either a high fat diet (HFD; 60% kcal 
from fat, 20% from protein, 20% from carbohydrate, Research Diets D12492) or a 
control, low fat diet (LFD; 10% kcal from fat) starting at 8 weeks of age. C57BL/6J HFD-
fed mice exhibited statistically worse glucose tolerance starting as early as 2 weeks after 
the start HFD feeding and was worse at 6 and 10 weeks after the start of HFD feeding 
(Figure 7A-C). As expected, mice fed a HFD had a significant increase in percent body 
fat compared to LFD-fed mice by dual-energy X-ray absorptiometry (DXA), and body fat 
increased over the timeframe of the study (Figure 7D). Taken together, these results 
establish that the HFD feeding paradigm leads to obesity and impaired glucose 
tolerance (IGT) over time. 
 C57BL/6J HFD-fed mice exhibited statistically increased body weights and 
fasting blood glucose values compared to control LFD-fed animals beginning at 6 weeks 
after starting the diet (Fig. 8A and B). We assessed glucose tolerance in HFD-fed mice 
on a weekly basis; as shown in Fig. 8C, glucose tolerance was statistically worse at 2 
weeks of age and continued through the end of the study. β-cell mass, as quantified 
histologically. increased significantly in HFD-fed animals compared to controls by 6 
weeks post diet initiation (Fig. 8D). Compared to LFD-fed control animals, HFD-fed mice  
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Figure 6: Mouse DMD assay specificity and validation. (A) Two-dimensional plots 
using plasmid standards for unmethylated and methylated mouse Ins2 DNA and for a 
1:1 mixture of the two plasmids. Arrows identify the unmethylated, methylated, and 
unmethylated + methylated (double-positive) Ins2 DNA-containing droplets. (B) 
Quantitation of plasmid dilution curves, presented as copies/μl. (C, D) Quantitation of 
dilution curves of serum spiked with mouse DNA for (C) unmethylated Ins2 DNA and (D) 
methylated Ins2 DNA. R2 = 0.9733 for unmethylated Ins2 DNA and R2 = 0.9917 for 
methylated Ins2 DNA. 
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Figure 7: Glucose Intolerance during LFD and HFD feeding in C57BL/6J. Mice were 
fed a LFD or HFD starting at 8 weeks of age. Every 2 weeks, a cohort of mice in each 
group was evaluated for glucose intolerance, and body fat content to determine 
correlation with β-cell death. (A) Glucose Tolerance Test after 2 weeks on diet; (B) 
Glucose Tolerance Test after 6 weeks on diet; (C) Glucose Tolerance Test after 10 
weeks on diet; (D) Area under the Curve (AUC) of GTT at 2 weeks of diet; (E) Area 
under the Curve (AUC) of GTT at 6 weeks of diet; (F) Area under the Curve (AUC) of 
GTT at 10 weeks of diet; (G) DEXA scanning after 6 and 10 weeks on diet. N=8 mice 
total for each of 4 groups, done on two separate occasions. Data are presented as mean 
± SEM; *P<0.05 for HFD at 6 weeks of diet compared to 10 weeks of diet, ***P<0.0001 
for HFD compared LFD.  
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exhibited episodic increases in unmethylated Ins2 DNA levels at 2 and 6 weeks post diet 
initiation (Figure 8E), coincident with the time points where glucose levels, fasting and by 
glucose tolerance test (GTT) were elevated (Figure 8B and C). By contrast, methylated 
Ins2 DNA levels were not statistically different in HFD-fed animals compared to controls 
across the feeding period. At 10 weeks after starting diet, LFD-fed mice were 
administered multiple low doses of STZ to induce overt β-cell death. As shown in Figure 
8E and F, unmethylated Ins2 (but not methylated Ins2) DNA levels increased 
significantly 1 week following STZ injections, then declined to baseline levels. The 
unmethylated Ins2 levels increased in HF-fed animals at two and six weeks of diet 
correlating to the first-time points demonstrating glucose intorelance and hyperglycemia. 
To correlate the serum β-cell death biomarker with a more traditional cell death marker, 
tissue sections were stained using the terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) assay. As shown in Figure 8G and H, STZ-treated mice exhibited 
increased β-cell death as evidenced by increased numbers of TUNEL+Insulin+ cells. In 
Figure 8H quantification of TUNEL+Insulin+ cells were quantified in pancreata sections 
across the whole pancreas to determine the ratio of β-cell death under HFD compared to 
LF-fed animals. Although no statistically significant increases in TUNEL+Insulin+ cells 
were seen at 2, 4 or 6 weeks of HFD feeding, a trend toward higher numbers were 
observed at 2 and 6 weeks of HFD feeding, correlating to the same timepoints at which 
we observed an increased in unmethylated Ins2.  
 
Absence of β-cell death in mice with established T2D.  
 Next, we applied the DMD assay to a mouse model of spontaneous T2D. The 
db/db mouse on the C57BLK/sJ background is an inbred strain that harbors a mutation 
in the leptin receptor gene and exhibits obesity, insulin resistance, β-cell dysfunction, 
and diabetes as early as 6 weeks of age on a normal chow diet (194).  
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Figure 8: Circulating unmethylated and methylated Ins2 DNA during LFD and HFD 
feeding in C57BL/6J mice. Mice were fed a LFD or HFD starting at 8 weeks of age. At 
11 weeks on diet, a cohort of mice in each group was treated with STZ to induce β-cell 
death. (A) Body weight measurements; (B) Fasting blood glucose measurements; (C) 
Area under the curve of intraperitoneal glucose tolerance tests; (D) β-cell mass; (E) 
Circulating unmethylated Ins2 DNA levels; (F) Circulating methylated Ins2 DNA levels; 
(G) Representative images of pancreata stained for insulin (green), glucagon (pink), 
TUNEL (red), and DAPI (blue); (H) TUNEL+/insulin+ cells per islet. N=6-12 mice total for 
each of 4 groups, done on two separate occasions; N=4 mice for staining, 5 sections per 
animal. Data are presented as mean ± SEM; *P<0.05 for HFD compared to LFD or for 
LFD-STZ compared to LFD.  
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 We serially collected sera from C57BLKS/J-db/db (henceforth referred to as 
“db/db”) and control C57BLKS/J-db/+ (henceforth referred to as “db/+”) mice weekly 
from 6 to 10 weeks of age and subjected them to the DMD assay. As shown in Fig. 9A, 
db/db mice remained significantly hyperglycemic compared to db/+ controls throughout 
this timeframe. No statistically significant differences were seen in unmethylated Ins2 
DNA (Figure 9B) nor were differences seen in Insulin+ cells at 5, 7, and 9 weeks (Figure 
10), findings that are consistent with prior studies that suggest that β-cell 
dedifferentiation, rather than loss, may be the major feature in db/db mice (181). 
Methylated Ins2 DNA exhibited a significant increase in db/db compared to db/+ controls 
at 7 weeks of age, but returned to control levels thereafter (Figure 7C). Collectively, 
these mouse studies indicate that β-cell death (as assessed by unmethylated Ins2 DNA 
levels) occurs episodically during the development of obesity and dysglycemia in mice 
and acutely upon β-cell killing by STZ, but persistent β-cell death is not detectable by our 
DMD assay in a mouse model of established T2D (db/db).  
 
III.C. Discussion 
 Measurement of circulating differentially methylated INS DNA has been gaining 
increasing attention as a minimally invasive biomarker of islet β-cell death that may be 
used to distinguish individuals with impending and new-onset T1D (186,187,189). 
However, much less is known about the characteristics of these DNA fragments in the 
setting of obesity and T2D. In this study, I applied the DMD assay to quantify circulating 
levels of unmethylated and methylated Ins2 in mouse models of obesity and T2D. These 
studies revealed a key finding not previously appreciated, notably that circulating 
unmethylated INS, a biomarker of β-cell death, increases episodically and transiently 
during the development of obesity and glucose intolerance in mice, but is not persistently 
elevated in established T2D. 
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Figure 9: Circulating unmethylated and methylated Ins2 DNA in C57BL/KsJ-db/db 
mice and controls. Cohorts of C57BLKS/J-db/db (db/db, N=16) and C57BLKS/J-db/+ 
(db/+, N=16) were followed between 6-10 weeks of age, and whole blood or serum was 
collected from 4-16 animals at each time point and assessed for: (A) Blood glucose 
levels, (B) Circulating unmethylated Ins2 DNA levels, (C) Circulating methylated Ins2 
DNA levels. Data are shown as mean ± SEM, *P<0.05 compared to corresponding 
values in db/+ animals. 
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Figure 10: Insulin staining of pancreas. Cohorts of C57BL6 fed HFD and LFD for 6 
weeks. Representative graph of pancreata stained for insulin; N=6-12 mice total for each 
of 4 groups, done on two separate occasions; N=4 mice for staining, 5 sections per 
animal. Data are shown as mean ± SEM, *P<0.05 compared to corresponding values of 
HF, # significantly different compared to other time point, One-Way ANOVA/Tukey’s. 
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 The loss of functional β-cell mass is believed to underlie virtually all forms of 
diabetes, but in T2D the primary etiology remains unclear. Autopsy studies have 
demonstrated increases in β-cell mass in adults with obesity and pre-diabetes compared  
to controls, and lower β-cell mass in individuals with frank T2D compared to controls 
(177,195). The loss in functional β-cell mass in T2D has been attributed variably to β-cell 
apoptosis and/or dedifferentiation (177,180,195), but definitive evidence for either is 
lacking. The DMD assay has been utilized by our group and others to monitor active β-
cell death in T1D, and provides an opportunity to assess contribution of β-cell death to 
the pathogenesis of T2D. 
 Methylation at CpG sites is an epigenetic modification that is correlated with 
silencing of genes. Therefore, genes that are mostly unmethylated at CpG sites show 
evidence of being actively or preferentially expressed (196). The mouse Ins2 gene is 
predominantly unmethylated at CpG site –182 bp (relative to the transcriptional start site) 
in islet β-cells, where its expression levels are greatest. In other cell types, Ins2 is mostly 
(though not completely) methylated at this site (185,188). Our lab has shown previously 
that the appearance of elevated unmethylated Ins2 in the circulation is reflective of dying 
β-cells that liberate their DNA (184,186). Utilizing ddPCR to measure levels of 
unmethylated and methylated Ins2, I report here that C57BL/6J mice placed on a HFD 
exhibit transient β-cell death (as reflected by increases in unmethylated Ins2) 
corresponding to time points where glucose levels were first increased during GTT (2 
weeks of feeding) and at fasting (6 weeks of feeding). The studies in this chapter 
suggest that measurement of unmethylated Ins2 may be a more sensitive measure of β-
cell death than quantitative tissue staining techniques, since the latter may be limited by 
sampling error. These findings in HFD-fed mice contrast with those in NOD mice (a 
model of T1D), where levels of unmethylated Ins2 DNA appear to remain persistently 
elevated during the dysglycemic pre-diabetic phase (184). Overtly diabetic db/db mice 
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showed no detectable elevations in unmethylated INS DNA levels compared to control 
db/+ animals during a 4-week period, suggesting that active β-cell death may not be a 
major ongoing feature in the setting of established T2D. These findings suggest that β-
cell death may be an episodic feature of obesity and dysglycemia. Further evaluation of 
ER stress gene and protein expression could help elucidate any correlation to these 
episodic elevations of unmethylated Ins2 and β-cell ER stress. In the studies presented 
in this chapter β-cell mass expansion was assessed by determination of β-cell density 
via immunofluorescence, other cells such as the α-cell within the microenvironment was 
not measured for expansion as we did not expect changes in this population under the 
conditions of the experiments. More studies are required to determine correlation 
between obesity in youth compared to effects in later stages and/or any links with 
pancreatic growth disorders (i.e. pancreatic cancer). 
 There are some caveats to the findings in this chapter.  First, given the short (~90 
min) half-life of DNA in the circulation (187), the episodic nature of β-cell death during 
obesity progression seen in my mouse models could easily be missed when studying 
cross-sectional human cohorts with obesity.  As such, my data emphasize the important 
of obtaining longitudinal collections in humans to assess the occurrence of β-cell death. 
Second, my DMD assay differs with respect to the targeted Ins2 gene CpG site 
compared to other DMD assays recently described (187–189). Therefore, it is necessary 
to cautiously compare findings between different assays, even in similar/identical 
populations (as different CpG sites can exhibit differing degrees of methylation durability 
with disease progression) (197). Third, and most importantly, my findings only apply to 
mice, and to date there are no definitive data (one way or the other) to suggest that the 
reduction in β-cell mass observed in humans with T2D arises from β-cell death.  Taken 
together, my findings in this chapter suggest that unmethylated Ins2 is a reflection of β-
cell death that can be detected in longitudinal cohorts of mice with obesity.  
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Chapter IV 
DHS as a modulator of β-cell replication during compensation 
 
In this chapter, I explore the adaptive response the β-cell undergoes during exposure to 
high fat diet. In particular, I test how DHS and eIF5A play roles in facilitating cell cycle 
progression during the compensatory phase of the β-cell to acute and chronic exposure 
to high fat diet. Experiments with PKCς kinase dead (PKCς-KD) mutant mouse were 
carried out in collaboration with the lab of Adolfo Garcia-Ocaña at the Icahn School of 
Medicine at Mount Sinai, New York. 
 
IV.A. Introduction 
 Although islet β-cells are limited in their ability to replicate, in postnatal life in both 
humans and rodents they undergo mass expansion to parallel the linear growth of the 
organism (51,91,198,199).  As such, this postnatal period (up to the age of 20 weeks in 
mice) represents the period of time when β-cell replication and its regulation has been 
studied.  As with any differentiated somatic cell type, most β-cells in the postnatal stage 
are mitotically quiescent, residing in G0 phase of the cell cycle. Upon mitogenic 
stimulation (linear growth of the animal, response to insulin resistance, etc.), β-cells 
enter cell cycle and proceed through the G1 phase, preparing for DNA replication. The 
transition from the G1 to S phase, in which cells double their DNA content, is the first 
“checkpoint” of the cell cycle, and as such is a regulated process (200). Subsequent 
passage through G2, then the M phase (the mitotic phase) allows the cellular 
components previously produced to be divided between the two daughter cells (201).  
The G2-M transition is also regulated in many cell types, and is considered a second 
“checkpoint” (202). Key proteins that regulate these checkpoints are the cyclin-
dependent kinases (CDKs). These proteins associate with other molecules, known as 
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cyclins, throughout the cell cycle to ensure timely progression (203). CDKs in turn are 
tightly regulated by CDK inhibitors to further safeguard the cell from progression of cell 
cycle in unfavorable circumstances (204).  
 In both rodents and humans, cyclin-D proteins are crucial in the progression of 
islet β-cells through the cell cycle. In rodents, an especially important role of cyclin D2 
was first described in the context of the normal postnatal β-cell expansion during linear 
growth of the animal. Mice deficient for cyclin D2 have impaired β-cell expansion and 
function (205). Cyclin-D1-deficient mice are small, with impaired neuronal, retinal, and 
mammary gland development (206,207), but appear to have no gross defects in β-cell 
replication per se (205). Cyclin-D3-deficient mice have reduced adipocyte size and 
increased sensitivity to insulin, but no obvious β-cell phenotype (208).  Cyclin-D activity 
accumulates in G1, as a function of mitogenic signaling. Restraining the conversion of 
glucose to lipids for storage by the cyclin-Ds allows the cell to use glucose-produced 
metabolites for production of cell content for cell division to take place (209). 
Alternatively, metabolism inhibition by the cyclin-Ds might provide a negative feedback 
to ensure unidirectional cell cycle progression. If metabolic activity increases cyclin-D 
expression, and cyclin-Ds inhibit metabolism, a rise in cyclin-D in G1 would shut down 
metabolism, therefore preventing re-entry into G1 until G1/S transition has completed.  
As noted above, cyclin-D2 is essential for normal postnatal β-cell growth and 
consequent glucose homeostasis in the growing animal. CyclinD2-/- mice develop 
diabetes owing to inadequate β-cell replication and mass (205). In addition, cyclin-D1 
appears to play a supportive role, since complex knockout/heterozygous cyclinD2-/-
/cyclinD1+/- mice show a much more severe β-cell growth deficiency than animals lacking 
either factor alone, resulting in death due to severe ketoacidosis as early as 4 months of 
age (205). Strikingly, however, these cyclins are not essential for β-cell proliferation 
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during pancreas development, since β-cell mass at birth appears normal in their 
absence (205).  
Feeding rodents a high fat diet (HFD) increases β-cell mass (69). The timing and 
identity of the enabling factors of the murine compensatory growth response are not 
comprehensively known, but it does appear that cyclin-D2 is essential in this process 
(210–212). Longitudinal studies in mice show that β-cell mass expands as insulin 
demand increases, and eventually declines as diabetes develops (213). The increase of 
β-cell mass could occur as a result of cell replication, hypertrophy, and/or neogenesis 
(214). Replication is believed to be the dominant mechanism for adult β-cell mass 
growth in mice (215), and by comprehensively cataloging these signals, the limitations to 
replication in adult β-cells could be ascertained.  
In the context of pathways that promote cell cycle entry, the growth factor 
signaling/mammalian target of rapamycin (mTOR) pathway has seen perhaps the 
greatest attention (210,211,216–219). However, a pathway that has received little 
attention has been the polyamines/eukaryotic translation initiation factor 5A (eIF5A) 
pathway.  Polyamines (putrescine, spermidine, spermine) and eIF5A have been 
extensively studied in the context of oncogenesis, as these factors promote cellular 
replication by enabling the translation of intracellular mRNAs during cellular growth 
(220,221).  Spermidine links the polyamines to eIF5A via the enzyme deoxyhypusine 
synthase (DHS). DHS is the rate-limiting enzyme that transfers an aminobutyl moiety 
from spermidine to the ε-amino group of Lys50 of eIF5A, to form the amino acid 
hypusine (hydroxyputrescine lysine) (221). This modification is required for all the known 
mRNA translational functions of eIF5A (222–224).  
The precise function of eIF5A in mRNA translation in mammals is still not well 
understood, but may be pleiotropic. Roles for eIF5A in ribosomal protein synthesis, RNA 
transport, mRNA stability, and polypeptide chain elongation have all been reported 
 56
(144,167,225–230). In the context of the β-cell, eIF5A appears to be important in the 
production of pro-inflammatory molecules and production of stress-responsive proteins 
in response to cytokine signaling and activation of the endoplasmic reticulum (ER) stress 
cascade (144,167,231).  However, no specific role for the polyamines or eIF5A have 
been ascribed to β-cell replication. In this chapter, I describe studies interrogating the 
role of the hypusine modification in compensatory β-cell replication.  Using a novel, β-
cell-deficient mouse model of DHS, I show that DHS is necessary for the proliferative 
response of β-cells to HFD feeding, and that the effect can be attributed to a specific role 
for DHS/eIF5A in enabling cyclin-D2 mRNA translation. 
 
IV.B. Results 
Generation of β-cell-specific Dhps knockout mice (Dhps∆β) 
 As shown in Figure 11A, our lab floxed exons 2-7 of the gene encoding DHS 
(Dhps) in mice.  Identification of mice harboring the floxed Dhps allele was identified by 
genotyping, as shown in Figure 11B.  I generated mice in which the Dhps gene was 
specifically and inducibly deleted in β-cells, by crossing DhpsloxP/+ mice to MIP1-
CreERTM mice (232) and breeding to homozygosity for deletion. To induce deletion of 
the Dhps gene postnatally, tamoxifen was administered to cohorts of animals at 
postnatal age of 8 weeks. I selected 8 weeks of age as a timepoint to induce DHS 
knockout since animals show evidence of β-cell replication at this age (199), therefore 
changes in mass and/or function of β-cells would be more noticeable. Dhps∆β mice and 
control littermates were allowed to acclimate for 1 week prior to further experimentation. 
To determine knockout specificity for β-cells, mice were euthanized two weeks after 
tamoxifen administration and islets, brain, liver and muscle were isolated. As expected, 
DHS protein levels were significantly reduced in the islets of the Dhps∆β mice compared 
to controls, and was unaffected in the liver and brain tissues tested (Figure 11C, D and 
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E). To further confirm the specificity of the recombination, a floxed Tomato fluorescent 
reporter gene in the Rosa26R locus was crossed into the breeding line. As shown in 
Figure 11F, recombination was observed only in β-cells by immunofluorescence staining 
of insulin by rabbit antibody and nuclear fluorescence of tomato+ cells (though the 
efficiency appears to be 50-60% of β-cells, a finding consistent with the known efficiency 
of the Cre driver strain via quantification of tomato+insulin+ of total insulin+ cells). To 
assess the metabolic impact of deletion of Dhps in β-cells, I measured body weight and 
glucose tolerance 1 week after tamoxifen treatment. As depicted in Figure 11G, no 
differences in weight between the Dhps∆β mice and the control littermates were 
observed. Additionally, Dhps∆β mice exhibited no differences in glucose tolerance when 
compared to the control littermates (Figure 11H). These studies suggest that deletion of 
Dhps in the β-cell does not acutely affect metabolic control. 
 
Loss of glucose tolerance and β-cell mass in Dhps∆β mice. 
 To test the role DHS in β-cell mass expansion, I next followed Dhps∆β mice and 
their littermates on both a normal chow diet (NCD, 16% kcal from fat) and on a high fat 
diet (HFD, 60% kcal from fat), as shown in the schematic in Figure 12A.  NCD-fed 
Dhps∆β mice appeared to exhibit a slight worsening of glucose tolerance after 4 weeks 
in the diet compared to the littermate controls (Figure 12B), however, this did not 
approach statistical significance by AUC analysis (Figure 12D). These data suggest that 
the loss of Dhps in β-cells has only a minimal impact on the normal growth responses of 
β-cells in young animals.  By striking contrast, knockout of Dhps led to evidence of frank 
diabetes compared to HFD-fed littermate controls based on fasting glucose 
measurements and glucose measurements following an intraperitoneal glucose load 
(Figure 12C and D). To further evaluate the cause of the glucose intolerance seen in the 
HFD-fed Dhps∆β mice, I conducted in vivo glucose stimulated insulin secretion assays  
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Figure 11: DHS Knockout mouse model is normoglycemic under basal conditions. 
DHS flox/flox mice were crossed with MIPCreRTm to obtain pancreatic islet beta cell specific 
DHS knockouts after 5mg Tamoxifen administration at 8 weeks of age. The model 
shows specificity to the islet. Mice showed no physiological effects following the 
knockout. (A) Schematic diagram of the Dhps gene targeting in flox/flox and wild-type 
mouse locus; (B) Electrophoresis gel of genotyping confirming DHS knockout; (C) 
Immunoblot of DHS protein levels in the pancreatic islet 2 weeks after Tamoxifen; (D) 
Immunoblot of DHS protein levels in the brain 2 weeks after Tamoxifen; (E) Immunoblot 
of DHS protein levels in the liver 2 weeks after Tamoxifen; (F) Immunofluorescence of 
DHS knockout mice carrying Rosa-26 Promoter expression; (G) Body weight 
measurement after 2 weeks of Tamoxifen administration; (H) Glucose Tolerance Test 
after 2 weeks of Tamoxifen injection. N=3 to 14 mice total. Data are presented as mean 
± SEM; *P<0.05 for DHS∆β compared to control.  
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(GSIS). Fig. 12E shows that insulin levels in Dhps∆β mice are similar to HFD-fed 
littermate controls after an overnight fast, but show significantly impaired insulin levels in 
response to the intraperitoneal glucose load.  
To determine if the glucose intolerance and reduced insulin response was due to 
decreased number of β-cells, I next examined β-cell mass in HFD-fed Dhps∆β mice and 
control littermates. Compared to control HFD-fed mice, HFD-fed Dhps∆β mice had  
significantly reduced (about 2-fold) β-cell mass (Figure 12F).  The reduction in β-cell 
mass in HFD-fed Dhps∆β mice could have resulted from either increased β-cell death or 
reduced β-cell proliferation.  To determine if the lack of β-cell compensation was due to 
increased β-cell death, I used the DMD assay (as presented in Chapter III) to measure 
β-cell death in HFD-fed control and Dhps∆β mice.  As shown in Figure 13A-D, I did not 
see an increase in β-cell death Dhps∆β mice compared to control animals at either the 
1-week or 4-week timepoints on the HFD, raising the likelihood that DHS impacts 
proliferation of β-cells.  
  In pursue of analyzing pathways that are affected by DHS deficiency in the β-
cells, high-throughput sequencing technology (RNA-seq) was utilized. RNA of isolated 
islets from mice fed HFD for 4 weeks was submitted to the Center for Medical Genomics 
in Indiana University School of Medicine. As expected, I found RNAs involved in cell 
growth pathways to be affected in the Dhps∆β mice compared to controls (Figure 14). 
The gene expression affected in HF-fed Dhps∆β mice compared to controls included 
downregulation of genes involved in DNA replication, mitotic nuclear division and 
regulation of developmental growth. Some of these genes found are: Neurofibromin 2 
(Nf2), Transforming growth factor beta 1 (Tgfb1), minichromosome maintenance 
complex component family (MCM2), checkpoint kinase 2 (Chek2), cell division cycle 45 
(Cdc45), cyclin-dependence kinase 1 (Cdk1), cyclin-dependent kinase inhibitor 1A 
(Cdkn1a), and Igf1 to mention a few. The misexpression of these genes could be the 
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result of β-cell compensation being impacted by the deficiency of DHS under HFD 
exposure.  
 
Increased glucagon expression after 4 weeks of HFD feeding in Dhps∆β mice 
 In addition to the limitation on processes of β-cell survival, β-cell dedifferentiation 
has been observed in vitro and ex vivo experiments (233,234). There is evidence of its 
occurrence in partial pancreatectomy studies, however, the possibility of occurring in 
T2D is yet to be explored. To evaluate if there are any changes on cell morphology in 
Dhps∆β mice after different time-points of HFD feeding. Pancreata of Dhps∆β and 
control mice was evaluated with confocal immunofluorescence using 
immunohistochemistry for insulin and glucagon hormone expression. I observed no 
differences in cell morphology and hormonal expression in the pancreata of 1 week HF-
fed mice (Figure 15A). However, glucagon expression was observed throughout the islet 
of 4 week HF-fed Dhps∆β mice whereas the controls had no detectable differences in 
glucagon expression (Figure 15B). The appearance of more glucagon expression in the 
4 week HF-fed Dhps∆β mice provide an explanation as to why these mice cannot 
compensate at this stage even though they were able to keep euglycemia at 1 week of 
HFD. 
 
Defects in β-cell proliferation are seen early following HFD feeding in Dhps∆β mice 
 Compensatory gains in β-cell mass in response to HFDs are reflected as 
increases in β-cell proliferation as early as 1 week following initiation of HFDs 
(54,211,212,235). To clarify the role of DHS in β-cell compensation, we therefore 
examined glucose tolerance, β-cell proliferation and β-cell mass in control and Dhps∆β 
mice after 1 week of NCD or HFD feeding. Notably, HFD-fed Dhps∆β mice exhibited 
significantly improved glucose tolerance compared to controls following 1 week of  
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Figure 12: Loss of DHS in the islet beta cell results in impaired glucose tolerance 
and beta cell mass decline. DHS∆β and control mice were subjected to 4 weeks of 
HFD feeding from 10 weeks of age. Mice showed impairment of glucose clearance via 
GTT, reduction of insulin secretion and decline beta cell mass. (A) Schematic diagram of 
feeding schedule of DHS∆β and control mice after Tamoxifen administration; (B) GTT of 
mice fed a normal chow diet (NCD); (C) GTT of mice fed a high fat diet (HFD); (D) Area 
under the Curve (AUC) of GTT; (E) Insulin ELISA of serum in vivo GSIS; (F) Beta cell 
mass calculation after 4 weeks of diet. N=3 to 14 mice total. Data are presented as 
mean ± SEM; *P<0.05 for DHS∆β compared to control.  
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Figure 13: Circulating unmethylated and methylated Ins2 DNA during HFD feeding 
in DHS∆β mice. Mice were fed a HFD starting at 10 weeks of age. A cohort of mice was 
sacrificed after 1 week on HF and another small cohort after 4 weeks of HFD. (A) 
Unmethylated copies of circulating Ins2 DNA in the serum after 1 week of HFD; (B) 
Methylated copies of circulating Ins2 DNA in the serum after 1 week of HFD; (C) 
Unmethylated copies of circulating Ins2 DNA in the serum after 4 weeks of HFD; (D) 
Methylated copies of circulating Ins2 DNA in the serum after 4 weeks of HFD. N=3-12 
mice total for each group.  
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Figure 14: Cell growth impaired in DHS∆β mice. RNA-seq of isolated islets from 4 
week HFD-fed DHS∆β mice. N=3-5. *P<0.05 compared to CTL.  
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Figure 15: Cell morphology changes after 4 weeks of HFD in DHS∆β mice. Mice 
were fed a HFD starting at 10 weeks of age. A cohort of mice was sacrificed after 1 
week on HF and another small cohort after 4 weeks of HFD. (A) Immunofluorescence of 
insulin and glucagon in DHS knockout mice after 1 week of HFD; (B) 
Immunofluorescence of insulin and glucagon in DHS knockout mice after 4 week of 
HFD.  
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feeding (Figure 16A, B and C). Consistent with this finding, circulating insulin levels in 
HFD-fed Dhps∆β mice were significantly higher than the controls (Figure 16D). At 1 
week of HFD, β-cell mass was not different between Dhps∆β and control mice (Figure 
16E).  On a NCD, no differences in glucose tolerance, circulating insulin, and β-cell 
mass were observed between Dhps∆β mice and littermate controls (Figure 16A-E).  
 To assess the role of DHS in β-cell proliferation during the compensatory stage 
of the β-cells, I first examined the activity of DHS by performing immunofluorescence 
using a custom hypusine-specific antibody created by our lab (236). EIF5AHyp levels were 
increased in islets after HFD-feeding in control mice, and appropriately reduced/absent 
in the Dhps∆β mice (Figure 17A). Next, we evaluated histological sections for 
proliferative cell nuclear antigen (PCNA). Whereas 1 week of HFD feeding increased the 
frequency of insulin+/PCNA+ cells compared to NCD in control littermates as expected, 
this increase was not apparent in Dhps∆β mice (Figure 17B and C). Taken together, 
these results suggest that DHS deficiency allows increased responsiveness of β-cell 
insulin secretion but is required for the early β-cell proliferative response to a HFD. 
 
Impaired cyclin-D2 mRNA translation in Dhps∆β HFD-fed mice. 
 To understand better the potential defects in cell cycle proteins that contribute to 
the phenotype of Dhps∆β mice, we evaluated mRNA levels for molecules involved in cell 
cycle progression at the G1/S boundary. We observed no differences in levels of several 
cell cyle mRNAs, including Ccnd2 (encoding cyclin-D2), Ccnd1 (encoding cyclin-D1), 
and Ccna2 (encoding cyclin-A2) in Figure 18A. Given the importance of cyclin-D2 in the 
early proliferative response to HFDs, we were surprised to see no differences in its 
mRNA in Dhps∆β mice.  We therefore next evaluated cyclin-D2 protein levels in islets, 
and as shown in Figure 18B and C, cyclin-D2 protein levels were significantly reduced in  
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Figure 16: Improved insulin secretion in DHS deficient β-cells mice after 1 week of 
HFD. DHS∆β and control mice were subjected to 1 week of HFD feeding from 10 weeks 
of age. DHS∆β  mice showed no glucose clearance impairment via GTT, and had more 
serum insulin compared to controls. (A) GTT of mice fed a normal chow diet (NCD); (B) 
GTT of mice fed a high fat diet (HFD); (C) Area under the Curve (AUC) of GTT; (D) 
Insulin ELISA of random serum insulin; (E) Beta cell mass calculation after 1 weeks of 
diet. N=3 to 14 mice total. Data are presented as mean ± SEM; *P<0.05 for DHS∆β 
compared to control.  
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Figure 17: DHS deficiency results in an impaired β-cell proliferative response 
following 1 week HFD. DHS∆β and control mice were subjected to 1 weeks of HFD 
feeding from 10 weeks of age. Mice showed no changes in overall beta cell mass, 
however, no induction of proliferation. (A) Immunofluorescence of eIF5AHyp of 11 week 
old mice fed 1 week of HFD; (B) Western Blot of eIF5AHyp of 11 week old mice fed 1 
week of NC and HF diets. Protein quantification of HF fed isolated islets; (C) 
Immunofluorescence of PCNA; (D) Quantification of PCNA and insulin positive cells. 
N=3 to 4 mice total. Data are presented as mean ± SEM; *P<0.05; **P<0.001 for DHS∆β 
compared to control.  
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Figure 18: Cyclin-D2 protein synthesis downregulated in Dhps∆β mice. Dhps∆β 
and control mice were subjected to 1 weeks of HFD feeding from 10 weeks of age. (A) 
qPCR isolated islets of mRNA; (B) Western Blot of Cyclin-D2 for 1 week HFD fed mice; 
(C) Protein levels of isolated islets of 1 week HFD fed mice for mRNA of Cyclin-D2. N=3 
to 5 mice total. Data are presented as mean ± SEM; *P<0.05 for DHS∆β compared to 
control.  
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Dhps∆β islets following HFD feeding. Collectively, these data suggest that DHS is 
necessary for the post-transcriptional regulation of cyclin-D2 levels in the β-cell.  
To determine if posttranscriptional regulation of cyclin-D2 levels is at the level of 
mRNA translation (and a possible role for eIF5AHyp at this level) we performed 
polyribosome profile (PRP) experiments on isolated islets of 1-week HFD-fed animals. 
PRP analysis involves sucrose gradient sedimentation of total RNA from islets, followed 
by monitoring of RNA distribution across the gradient by UV absorbance. RNAs 
associated with different components of the ribosome assembly complex sediment 
differentially, such that those associated with monoriboosomes sediment early, and 
those that are associated with multiple ribosomes (polyribosomes)—and hence are 
actively translated—sediment later in the gradient (237,238). We found the overall profile 
of Dhps∆β islets to be unchanged compared to control islets, with the “polyribosome-
monoribosome (P/M) ratio” (reflecting the relative association of RNAs with 
polyribosomes to monoribosomes) to be statistically unchanged (Figure 19A and B).  
This result suggests that the global translational profile of the RNAs are unaffected by 
deletion of Dhps in β-cells, a finding consistent with the absence of a role for DHS/eIF5A 
in generalized mRNA translation.  However, to interrogate the translation of specific 
mRNAs, I next collected fractions from the sedimentation gradient and isolated total 
RNA, and subjected them to RT-PCR for cyclin-Ds. As shown in Figure 19C and D, the 
mRNA encoding cyclin-D2 (Ccnd2) exhibits a clear shift in occupancy toward 
monoribosomes in Dhps∆β islets compared to control islets, indicating an absence of 
engagement of this mRNA with polyribosomes in Dhps∆β islets. By contrast, no changes 
in the engagement of Ccnd1 mRNA was observed in Dhps∆β islets as shown in Figure 
19E and F. Collectively, these results suggest that the impaired proliferative response in 
islets of HFD-fed Dhps∆β mice is due to impaired translational engagement of Ccnd2.  
                         
 70
               
Figure 19: Cyclin-D2 protein synthesis halted by translation initiation block in 
Dhps∆β mice. DHS∆β and control mice were subjected to 1 weeks of HFD feeding from 
10 weeks of age. (A) PRP of isolated islets from DHSKO and Ctl treated 1 week HFD; 
(B) P/M Ratio of transcriptome of isolated islets; (C) qRT PCR of fractions from PRP for 
mRNA of Cyclin-D2 ; (D) P/M Ratio of fractions for Cyclin-D2; (E) qRT PCR of fractions 
from PRP for mRNA of Cyclin-D1; (F) P/M Ratio of fractions for Cyclin-D1. N=3 to 5 mice 
total. Data are presented as mean ± SEM; *P<0.05 for DHS∆β compared to control.  
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The DHS/eIF5A pathway lies downstream of PKCζ activation, and in parallel to mTOR 
regulation of mRNA translation. 
As noted previously, a key pathway that links extracellular mitogenic signals to 
activation of mRNA translation and β-cell proliferation is the growth factor/mTOR 
pathway (210,211,216–219). To determine how the growth factor/mTOR pathway might 
be linked to polyamines/DHS/eIF5A pathway, we collaborated with the lab of Dr. Adolfo 
Garcia-Ocaña at the Icahn School of Medicine at Mount Sinai. The kinase PKCζ lies 
proximal to mTORC1 (239,240), and in mice harboring kinase-dead-PKCζ (KD-PKCζ) 
protein in β-cells (β-KD-PKCζ), the proliferative response to obesity and insulin 
resistance is impaired, similar to Dhps∆β mice (211). First, we examined the levels of 
eIF5AHyp in the islets of HFD-fed β-KD-PKCζ mice by immunoblot. As shown in Figure 
20A, eIF5AHyp levels were increased in control animals fed a HFD, consistent with our 
own data (Figure 17B). However, eIF5AHyp levels did not increase in islets upon HFD 
feeding of β-KD-PKCζ mice (Figure 20A). These findings suggest that PKC ζ loss may 
impact DHS/eIF5A, and suggests that the phenotype of β-KD-PKCζ mice maybe 
referable to the loss of hypusine formation.  To confirm that PKC ζ is upstream of DHS, 
we next examined if activation of PKCζ (via its phosphorylation at residue T410) 
occurred in Dhps∆β mice.  As shown in Figure 19B, control and Dhps∆β animals on a 
NCD showed minimal immunostaining for p-PKCζ in islets; by contrast, control animals 
and Dhps∆β animals on a HFD showed apparently equivalent immunostaining intensity 
for p-PKCζ, suggesting that activation of PKCζ is unimpaired in the absence of Dhps 
(Figure 20C). Collectively, these data suggest that PKCζ activation is unaltered in the 
absence of DHS activity and its loss impacts hypusine formation. 
Next, to clarify the relationship between the DHS/eIF5A pathway and mTOR 
activity, we utilized the murine β-cell-derived line MIN6. We treated MIN6 cells with 0.5 
mM of the free fatty acid (FFA) palmitate as a model in vitro to mimic the HFD effects in  
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Figure 20: P-PKCζ knockdown affects upstream of DHS activity. PKC KD, DHS∆β 
and control mice subjected to 1 weeks of HFD feeding from 10 weeks of age. (A) 
Immunoblot of eIF5AHyp in isolated islets from PKC knockdown mice fed a standard diet 
SD or a HFD, quantification of the immunoblots; (B) Immunofluorescence of pancreas 
sections from DHS∆β mice fed SD for 1 week; (C) Immunofluorescence of pancreas 
sections from DHS∆β mice fed HFD for 1 week. N=3 to 4 mice total. Data courtesy of the 
lab of Dr. Adolfo Garcia-Ocaña at the Icahn School of Medicine at Mount Sinai. 
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mice.  Cells were then treated with N1-Guanyl-1,7-diaminoheptane (GC7, a potent and 
specific inhibitor of DHS (241)) or vehicle, and subjected cell extracts by Reverse Phase  
Protein Assay (RPPA). As shown in Figure 21 and consistent with prior studies (242), 
palmitate activated components of the mTOR signaling pathway. Notably, inhibition of 
DHS with GC7 did not affect activation of this pathway. Further studies are needed to 
evaluate other molecules that showed downregulation by the GC7 treatment such as the 
ER stress molecule immunoglobulin heavy–chain binding protein (BIP) and the ATP-
dependent helicase X-linked helicase II (ATRX). These findings may suggest that the 
DHS/eIF5A pathway downstream of PKCζ, but likely in parallel with mTOR signaling.   
  
IV.C. Discussion 
 Potential approaches to increasing β-cell mass and function during the 
prediabetic phase of the disease has being gaining an increasing interest in the field 
(243). The work in this chapter significantly advances our knowledge of the pathways 
that control β-cell proliferation, and provide a novel contribution on the role of 
polyamines/DHS/eIF5A in this process. The focus on DHS in this chapter emanated 
from studies in the literature attributing a role of this enzyme in cellular 
proliferation/oncogenesis (244–246). Utlizing a novel mouse model not previously 
described, and subjecting mice to a β-cell mitogenic stimulus, my work in this chapter 
identified several new findings β-cell proliferation: (a) DHS and its hypusine modification 
of eIF5A is necessary for the β-cell proliferative response to HFDs in mice, (b) DHS is 
necessary for the translational engagement of the Ccnd2 mRNA encoding cyclin-D2 
during the stimulus for β-cell proliferation, (c) activity of DHS requires intact PKCζ 
signaling, but is not may be required for mTOR activation.  
 The model I employed in this chapter has been utilized by many investigators to 
demonstrate the capacity of β-cells to proliferate in young mice (212,235,242,247). In my  
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Figure 21: mTOR pathway unaffected by chemical inhibition of DHS activity. 
Reverse Protein Profiling Array of total cell lysate of MIN6 treated with Palmitate for 24hr 
and GC7. N=3-5. *P<0.05 compared to CTL. 
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study, β-cell mass was measured at two different time points and demonstrated how the 
block of proliferation as early as 1 week of HFD resulted in a detrimental decrease of β-
cell mass by 4 weeks of HFD. The timing of early induction of proliferation in HFD 
coincides with the hyperglycemia and hyperinsulinemia because both glucose and 
insulin have been described to induce proliferation and mass increase in rodents in the 
setting of chronic insulin resistance (248). Continuous hyperglycemia in vivo induced 
proliferation as early as 4 to 7 days after the start of HFD feeding (242). In this study, I 
confirmed that the levels of hypusination of eIF5A increase in the pancreatic β-cell in 
response to HFD. This finding explains why we did not see any significant changes 
following the induction of the DHS knockout. I observed hyperglycemia during both 
fasting and nonfasting states of the Dhps∆β mice after 4 weeks of HFD whereas after 1 
week of HFD Dhps∆β mice had better response in GTT, indicating that insulin levels are 
not adequate in the 4 week HFD either by dysfunction or due to a lack of β-cell mass 
compensation but that DHS deficiency allows for the β-cell to compensate by increasing 
insulin production and secretion for a short period of time. Because I saw significantly 
reduced β-cell mass after 4 weeks of HFD in Dhps∆β mice, it suggests that DHS and 
eIF5AHyp are together responsible for β-cell mass compensation. To determine if the lack 
of β-cell mass compensation was due to increased β-cell death, I used the DMD assay 
(as presented in Chapter III) to measure β-cell death in control and Dhps∆β mice and did 
not see differences in β-cell death, strongly suggesting that DHS regulates proliferation 
during the early compensatory phase.  It is important to point out that the study 
presented in this thesis only evaluated the physiological and molecular effects in a short 
window, up to 4 weeks of HFD. Recent studies of mice fed a 42% HFD for 16-weeks 
showed evidence of activation of p53 and reduction in global protein translation (249). 
This study suggests that p53 plays a role in modulating translation and not transcription 
of mRNAs during chronic exposure of HFD in the islets.  
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 I explored translational changes during the early stages of β-cell proliferation in 
response to HFD, focusing on direct regulators of cell cycle progression. Cyclin-D2 is the 
most important D-cyclin expressed in the β-cell postnatally essential for adult β-cell 
replication (102). This cyclin forms a complex with and functions as a regulatory subunit 
of CDK4 (in the case of rodents) and CDK6 (in humans), whose activity is required for 
cell cycle G1/S transition.  It has previously been shown in the literature that there is an 
increase in cyclin-D2 protein but not mRNA is present during the response to HFD (212). 
Pancreatectomy studies in mice have shown cyclin-D2 mRNA to be unchanged in the 
pancreas, but protein levels increased (250). The three D-cyclins contain a 
phosphorylation site near their carboxyl terminus. It has been shown that mutation of 
Cyclin-D1 on Thr286 (Threonine286) in mouse embryo fibroblast cell line (NIH3T3) 
resulted in an increase in proteosomal degradation (251). A more recent study done in a 
mouse model with cyclin-D2 protein with a mutation on the residue Thr280 to an alanine 
resulted in a much higher level of protein expression compared to controls despite 
similar levels of mRNA amounts (250). These studies suggest Cyclin-D2 to be regulated 
at the protein level, but do not delineate the possible pathways that facilitate an increase 
on Cyclin-D2 translation under certain conditions despite no changes in mRNA 
expression. No changes in Cyclin-D2 degradation were observed in response to 
palmitate treatment in MIN6 studies. I have found that this upregulation of cyclin-D2 
protein is dependent on hypusination of eIF5A, since in our Dhps∆β mice showed a 
block of translation leading to significantly reduced protein levels. The results in this 
study show a potentially novel translational regulatory pathway of DHS influencing 
cyclin-D2 protein levels in the β-cell under conditions of hyperglycemia and insulin 
resistance.  
PKC-ζ is a relatively novel protein downstream target of phosphatidylinositol 3-
kinase-phosphoinositide-dependent kinase-1 (PDK-1). This kinase is critical for 
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mitogenic signal transduction in many cell types such as fibroblasts, oocytes and glial 
cells (252,253). Studies in transgenic mouse models of parathyroid hormone-related 
protein (PTHrP) and hepatocyte growth hormone (HGF) driven by rat insulin promoter 
(RIP) showed that activation of PKC-ζ resulted in β-cell proliferation (239). Recent 
studies of KD- PKCζ or by disruption of PKCζ in mouse β-cells resulted in inhibition of 
compensatory proliferation under acute hyperglycemia/hyperinsulinemia (254). The 
mammalian target of rapamycin complex1 (mTORC1) is a protein complex that functions 
as a nutrient/energy sensor controlling protein synthesis. One of its most studied roles is 
its activation of protein translation to facilitate cell growth and proliferation. mTOR is 
activated via the serine/threonine kinase Akt pathway activation. It has been suggested 
in the literature that PKCζ  activates early compensation independent of Akt mediated 
mTOR activation (254). To date, little is known about the regulation of DHS activity. 
However, based on our data presented here, PKCζ is upstream of hypusination of eIF5A 
as we showed using kinase dead PKCζ mice a significant reduction of eIF5AHYP when 
fed HFD compared to controls. However, there was no difference in phosphorylated 
PKCζ in our DHS∆β mice compared to controls, confirming our initial assessment of 
PKCζ being upstream of DHS activation.  
 Until now, the intracellular pathway of PI3K/Akt/mTOR has been the predominant 
pathway linking cellular quiescence, proliferation, and longevity of the β-cell. In this 
chapter, I provide the first evidence that the DHS/eIF5A pathway functions in a parallel 
fashion to mTORC1, but like mTORC1, lies downstream of PKCζ. The precise link 
between PKC ζ and hypusine formation still remain unclear.  For example, does PKCζ 
directly regulate ODC and/or DHS, thereby regulating hypusine formation?  Or perhaps 
PKCζ controls another factor (kinase, acetylase, etc.) that subsequently regulates ODC 
or DHS (Figure 22)?. These and other questions must await further study. Overall, these 
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studies suggest PKCζ and the polyamine pathway to be parallel in their ability activate 
cell growth and simultaneously influence activation of DHS and therefore eIF5A activity. 
 
 
 
 
Figure 22: Novel pathway of early compensatory proliferation in the pancreatic β-
cell. In the presence of hyperglycemia and insulin resistance PI3K and the polyamine 
pathway are simultaneously activated. PI3K leads to activation of PKCζ which in turn 
activates mTORC1 to regulate protein synthesis for proliferation. PKCζ also facilitates 
the activation of DHS for hypusination of eIF5A resulting in an increase in Cyclin-D2 
protein translation leading to compensatory β-cell proliferation. 
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Chapter V 
Conclusions and Future Directions 
 
The research presented in this dissertation provides novel insight into the 
molecular pathways by which the β-cell mass compensates and decompensates—that 
is, responds in size and functional capacity—to changing metabolic demands. Generally, 
these responses include (1) an adaptive proliferative response to a nutritional challenge 
(Chapter IV) and (2) a maladaptive response in which β-cells are triggered to senesce if 
the compensatory responses are insufficient to restore euglycemia and re-establish 
equilibrium (Chapter III). The mechanisms of adaptive compensation are critical to 
maintain an appropriate range of serum glucose levels in organisms that are exposed to 
an environment of “overnutrition,”—that is when available energy exceeds the 
organismal needs for normal growth, development, and metabolism—as might be 
expected in the setting of obesity. This final chapter will summarize the major 
accomplishments of this dissertation study and place them into both the historical and 
contemporary contexts provided in the introductory chapter. Importantly, this chapter will 
also consider the possible future research questions that stem from the current research. 
 
V.A. The adaptive response to overnutrition: β-cell replication  
The seminal studies of Ogilvie (255) and Butler (44) established the associations 
between islet size, obesity, and diabetes. The activation of β-cell proliferation in 
response to overnutrition is not only crucial to maintain euglycemia at the early stages of 
overnutrition, but becomes even more important at later stages with the onset of insulin 
resistance. As previously described, the mechanisms regulating postnatal β-cell 
proliferation are complex, comprising multiple molecular pathways that are highly 
 80
interdependent (for example, see Figure 3). The longstanding interest in understanding 
these mechanisms has been fueled by their tantalizing potential to provide novel 
therapeutic targets that could potentiate survival and function of the β-cell. Previous work 
in our lab has demonstrated that pathophysiological glucolipotoxicity, thought to be 
perhaps the instigator of postnatal proliferation,  and β-cell mass loss by apoptosis 
despite intact signaling processes (242,249). The data in this dissertation suggest that 
glucolipotoxicity promotes postnatal proliferation early on via DHS activation during HFD 
exposure.  The studies I have presented in this dissertation provide evidence not only 
that the early proliferation response to HFD seen in mice is ultimately essential to 
prevent diabetes development, but also that DHS and its subordinate eIF5A are involved 
in this late postnatal increase in proliferation. Moreover, DHS and eIF5A facilitate the 
translation of specific transcripts, including crucial cell cycle progression molecules like 
cyclin-D2. Whereas a recent study in yeast suggested that eIF5A (and its bacterial 
homolog, EFP) is required for translational facilitation of stretches of nascent 
polypeptides containing poly-proline stretches of as few as two consecutive proline 
residues (226,256), this finding has not been confirmed in mammalian cells, whose more 
complex proteome contains a plethora of poly-proline-containing proteins (257). In the 
case of cyclin-D2, poly-proline stretches do not exist, and therefore the potential that 
eIF5A has more complex roles in mammalian biology is very likely. Nevertheless, the 
selective nature of eIF5A with respect to transcript recognition raises the need to 
address its mechanism using approaches such as ribosome footprinting.   
Following the initial observations of nutrition-mediated β-cell proliferation in 
postnatal rodents (212,235,258), several subsequent reports hypothesized that this 
response could also be occurring in humans, and that its manipulation could be the key 
to therapies for diabetes (44). However, clinical findings to support this response in vivo 
are lacking for multiple reasons. These include the inability to study subjects 
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longitudinally, since there are no reliable non-invasive techniques that currently can be 
applied in humans. Thus, only human pancreatic tissues routinely available for study are 
recovered from cadaveric sources. The challenges associated with working with this 
tissue source significantly limits data collection and interpretation. One possibility to 
overcome the limitations encountered in studying human β-cell dysfunction is by the 
development of a non-invasive assessment of functional β-cell mass via ultrasound or 
magnetic resonance imaging (MRI) but without the risk of high concentrations of 
radioactivity exposure. Blood tests have been found to be helpful in diagnosing diabetes 
but not preventing it, therefore an assessment that would allow the longitudinal study of 
the human islets could provide massive advantages in the field. However, the recent 
development of a non-invasive β-cell biomarker measuring its viability (as explained in 
Chapter III), could shed light into understanding β-cell mass changes in humans over 
time. One could also argue that this assay could be measuring actual stress levels 
instead of death or failure to proliferate resulting in the release the β-cell DNA as an 
autocrine signal. 
Previous studies in mice have suggested that compensatory proliferation occurs 
very early in the development of diabetes in response to overnutrition, even prior to 
insulin resistance (212,235,242). In Chapter IV of this dissertation, the process of β-cell 
compensation in the presence of elevated glucose/FFAs was investigated. Specifically, 
since hypusinated eIF5A has been shown to play an important role in cell cycle 
progression in other cell types (246), we studied the roles of hypusinated eIF5A and 
DHS during proliferative compensation of β-cell mass. This was a novel direction, as 
previously all roles identified for DHS and eIF5A in the pancreatic islet have focused on 
the inflammatory responses in T1D and T2D mouse models with only pharmacologic 
manipulation (144,167,225,259). Regardless, an emerging interest in understanding how 
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the β-cell undergoes proliferation in response to increasing insulin demand represents a 
need in the field to be elucidated. 
Studies measuring β-cell replication have shown that proliferation in adults is 
diminished with age (260). In those studies, it was suggested that younger β-cells can 
re-enter the cell cycle immediately after mitosis; however, the quiescent interphase 
period is lengthened with age and shortened by elevated metabolic demands. We 
determined that DHS deletion in mouse β-cells did not cause any detrimental effects 
under basal conditions, at least over a short time span. The evidence for this conclusion 
was based on the comparison of Dhps∆β mice and controls, which showed no difference 
in any of the physiological or molecular characteristics examined, including: enhanced 
sensitivity to glucose tolerance at 1 week of HFD, cell morphology, and insulin/glucagon 
expression. Moreover, injury studies have further supported the age-related loss of 
proliferative capacity. For instance, β-cell proliferation following partial pancreatectomy, 
and treatment with low-dose STZ and a glucagon-like peptide 1 agonist (261) showed 
that proliferation was stimulated in young mice but significantly diminished in old mice 
(261). In these studies, it was found that the adaptive compensatory proliferation that the 
β-cell can undergo under certain stimuli was severely restricted with advanced age in 
mice. These experiments suggest that middle-aged mice are largely post-mitotic and 
young mice may not be a good model for studying regenerative capacity of the β-cells. 
As such, future studies with regard to replication activation could be performed to identify 
what molecular pathways are involved and therefore induction of β-cell replication could 
be performed to specifically determine if increases on a particular molecule facilitates or 
inhibits further replication. Of particular interest is whether other tissue growth factors 
may stimulate endogenous regeneration of β-cell mass in patients of different ages with 
newly diagnosed or long-standing diabetes (262). 
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Of clinical importance is the improved understanding of signals that regulate 
growth and maintenance of the β-cells. Many advances have been made involving 
molecular determinants that allow cell cycle progression from the G1 phase of the cell 
cycle. In this context, cyclin-D2 contributes to β-cell replication. A potential challenge to 
translating this finding to humans is that the molecular triggers for β-cell replication in 
mice and humans are not the same. It has been shown, however, that β-cell replication 
indeed is the primary mechanism of growth during infancy and adolescence in humans 
(91). Other studies have reported that obesity and aging increase the replicative capacity 
of the β-cell by ~50% and that β-cell mass is actually preserved in human aging (263). 
Importantly, however, is that the data on cell cycle regulation in β-cell replication is 
mostly from rodent model studies, and whether these findings can be extended to 
human β-cells is still unknown. Together, my results strongly suggest future studies to 
more precisely measure the turnover rate of the human β-cell and whether this can be 
modulated, as in mice, to meet the need for more insulin via β-cell replication. 
Of importance for future study is the fact that there is another factor that may 
affect the β-cells capacity to overcome stimuli via replication, that is the possibility of the 
cells not being fully differentiated. Studies interrogating β-cell proliferation with adaptive 
β-cell function have found that there are two processes of β-cell dysfunction, death and 
dedifferentiation (264). In fact, studies done in humans scoring dedifferentiated β-cells 
showed that β-cells accounted for >30% dedifferentiation in T2D cases compared to 
controls (265). An important direction for future research will be to generate a mouse 
model were β-cell dedifferentiation can be triggered into other endocrine cells, mimicking 
the findings in humans with T2D.  
In Chapter IV, mechanisms of action to activate DHS and therefore adaptive 
proliferation in the β-cell was examined in vivo in collaboration with Dr. Adolfo Garcia-
Ocaña’s lab at Mt. Sinai NY. Our results suggested that DHS activity lies downstream of 
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PKCζ, but in parallel with mTORC1 (Figure 21).  This finding serves to link the 
previously-studied mTOR pathway to DHS/eIF5A, and therefore opens new possibilities 
regarding the manipulation of β cell replication.  For example, could limitations in β-cell 
replication in aging β-cells be a result not of activation of mTORC1, but rather some 
limitation linking growth factor signaling to DHS/eIF5A? 
 
V.B. The maladaptive response to overnutrition: β-cell death 
To probe the relationship between excess nutrition and β-cell death, the studies 
described in Chapter III investigated the capacity of a non-invasive biomarker to detect 
β-cell death in vivo in mouse models. Specifically, these data suggest that differential 
methylation of the preproinsulin gene can be utilized as a potential technique to 
diagnose β-cell viability. Other studies similarly designed by other groups may 
complement our approach to confirm the diagnosis (266). In this regard, I hypothesize 
that if applied to humans, the detection of different levels of preproinsulin DNA in the 
circulating blood could direct personalized therapies that could prevent or alleviate the 
development of diabetes. 
In our studies, consistent with other reports, exposure of C57BL/6J mice to high fat diet 
(HFD) was sufficient to induce hyperglycemia. Moreover, the BL/6J mice gained a 
significant amount of weight in conjunction with the development of hyperglycemia. This 
was in accord with previous studies that showed an increase in the rate of diabetes 
development in BL/6J mice (247). Additionally, the β-cells of the BL6 mice showed to 
have the capability to sustain more environmental changes. This could be due to their 
different genetic backgrounds, as it has been published that other strains are a more 
heterogenous genetic strain than BL/6J mice (247). Nevertheless, the observed effects 
in the BL/6J mouse strain were markedly expected suggesting that β-cells undergo 
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death in a wave pattern, and death triggers mechanisms that result in temporarily 
controlling hyperglycemia for a number of weeks until multiple death patterns occur and 
the resurgence to health no longer happens. Our data presented in Chapter III suggest 
that because of its sensitivity, this ddPCR/biomarker technology would be invaluable in 
screening for diabetes at an earlier point in its natural history, before extensive β-cell 
loss has occurred. Diabetes is typically diagnosed by a failed oral glucose tolerance test 
that shows fasting blood glucose over 100 mg/dL and 1hr postpandrial blood glucose of 
140 mg/dL or more. Obviously, this method of diagnosis increases the rate for macro- 
and micro-vascular complications in the individual. This early detection in turn might 
facilitate the implementation of more efficacious interventions that could stop or reverse 
its course. Some examples of possible interventions to aid with diabetes currently used 
are exogenous insulin, glucose level controlling medications (Metformin), regimen of diet 
and exercise. However, these interventions could have better outcomes in preventing 
future complications in diabetic patients if there was early diagnosis. By early 
intervention, the disease could possibly be prevented without any pharmacological 
intervention.  
Indeed, our study and others have contributed in developing this technology that 
could help detect early signs of β cell distress and death and give clinicians a window for 
treatment that could better the outcomes and/or completely prevent the further 
development of the disease. In this regard, similar technology has been utilized in other 
fields with significant success. One example is prenatal cell-free DNA screening which is 
a widely used method to screen for chromosomal abnormalities in a developing fetus. 
First reports of the presence of fetal cells in maternal blood was first explained in 1969, 
were the possibility of isolating cells to identify possible genetic abnormalities was then 
born (267–269).  
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V.C. Stress-induced plasticity of β-cells: a fate better than death? 
In these studies, we assessed changes in β-cell mass via proliferation and death 
which may be directly attributed to increased metabolic demands. Similarly, many β-cell 
injury models have shown that β-cells are capable of recovering from massive insults via 
self-duplication. However, other studies have shown that β-cell mass may respond to 
metabolic stresses through changes in cell fate—either conversion of non-beta cells into 
insulin-expressing beta cells, or de-differentiation to non-insulin expressing cell types. 
For instance, alpha cells may “trans-differentiate” into β-cells in order to compensate for 
the lost functional beta cell mass (270). In contrast, the transcriptional regulator FoxO1 is 
required to maintain β-cell fate under stress (264). It is possible that this parallels the 
studies in this thesis, as their findings of dedifferentiation of β-cells in the FoxO1-
deficient β-cell mouse model that resulted in an elevated number of α-cells seems very 
similar to findings in which the pancreatic morphology of Dhps∆β mice after an extended 
exposure to HFD. The increase in glucagon-expressing cells seem to be associated with 
DHS deficiency in the particular diet regimen. Nevertheless, induced compensatory β-
cell proliferation seems to be mainly guided by self-replication more than any other 
mechanism. Studies evaluating cyclin-D2’s role in β-cell proliferation also showed similar 
results in an increase in glucagon expressing cells after an extended period of time. 
Alternatively, our findings may be the result of cyclin-D2 protein deficiency rather than a 
direct effect of DHS deficiency. Although it should not be disregarded in this study that 
other mechanisms are contributing to the resurgence of β-cell mass growth after or 
during an environmental insult of either acute or of chronic nature.  
A future direction based on my research would be to establish how exactly the 
hypusinated eIF5A affects protein synthesis of cyclin-D2. To date, preliminary findings of 
RNA immunoprecipitation studies have shown that cyclin-D2 mRNA may be bound 
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directly to hypusinated eIF5A where its translation is then facilitated. In fact, levels of 
Ccnd2 message did not change throughout our studies, suggesting that indeed 
translation is the main mechanism responsible for controlling proliferation postnatally. In 
contrast, deletion of cyclin-D2 in the pancreatic β-cell results in similar findings as with 
the deletion of DHS (205). These findings thus suggest a need in the field to identify 
precisely which mitogenic signals and activated pathways are responsible for the 
increase in DHS activity. Yet the finding that DHS and by consequence, hypusinated 
eIF5A, are responsible for proliferative response is not one that is entirely surprising as 
the combination has been linked to proliferation in other cell types and diseases (271). 
Future studies are thus warranted that will examine in more detail precisely how DHS 
aids in early compensation of the β-cell and when does this positive outcome switches 
into a detrimental consequence to the β-cell. 
The observation in Chapter III that hyperglycemia follows spikes of β-cell death is 
a phenomenon that even though somewhat discussed in literature, it has never been 
presented in this level of detail. An initial hypothesis was that perhaps β-cell death would 
be seen once followed by hyperglycemia and that then followed by the development of 
diabetes. Yet studies presented in Chapter III refute this hypothesis and rather suggest 
that waves of β-cell death may occur multiple times throughout a chronic exposure to 
HFD in mice before frank diabetes develops. Future research could be directed at 
determining whether this particular aspect of β-cell function in the mouse HFD model 
has similarities to humans and how intact is β-cell function following the waves of β-cell 
loss—though this will require the development of better non-invasive techniques of 
monitoring beta cell mass. One testable hypothesis is that β-cell death is likely to be 
triggered as they succumb to exhaustion while simultaneously enhancing insulin 
secretion and self-duplication to ensure that glucose homeostasis is preserved.  
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Alternately, the rise in β-cell death at certain points during the HFD protocol could 
be explained by the progressive activation of other stress response pathways, such as 
those involving NF-κB. This in turn could result in the additional production of reactive 
oxygen species and the depletion of ER calcium (272), which together would trigger cell 
death. Indeed, our data suggest that distinct therapeutic approaches may be required to 
promote β-cell survival in T1D and T2D. Yet these studies suggest that these processes 
end up activating a similar end result through NF-κB resulting in ER stress provoking a 
stress response that could give signs of approaches to reduce the effects of β-cell death 
in both instances. Importantly, stress responses such as the unfolded protein response, 
which block translation are adaptive in the short term, and serve to maintain the overall 
functional capacity of the system. However, the question remains whether it is possible 
to appropriately control the switch between maintaining β-cell mass and maintaining β-
cell function.  
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